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Zusammenfassung 
 
Heilpflanzen dienen als primäre Gesundheitsversorgung in den meisten 
asiatischen und afrikanischen Ländern. In westlich geprägten Ländern in denen 
hauptsächlich auf naturwissenschaftlichen Grundsätzen basierende Medizin 
praktiziert wird, werden Stoffe aus pflanzlicher Herkunft entweder direkt als 
Kräuterformulierungen oder als Ergänzung zu bestehenden Therapien verwendet. 
Daneben können Pflanzen mit aktiven Wirkstoffen auch Teil der Ernährung sein. Es 
besteht die allgemeine Überzeugung, dass pflanzliche Heilmittel aufgrund ihres 
natürlichen Ursprungs sicher sind. Daher werden sie oft im Rahmen 
selbsttherapeutischer Maßnahmen verwendet und sind in Deutschland auch nicht 
rezeptpflichtig. Diese Arbeit beschäftigt sich mit der Bioaktivität, Wirkungen aber auch 
potentiellen Nebenwirkungen derartiger pflanzlicher Heilmittel. Hierbei stehen 
Extrakte aus Erythrina excelsa sowie die Substanz Ecdysterone im Mittelpunkt des 
Interesses. Erythrina excelsa ist eine Pflanze die in der kamerunischen traditionellen 
Medizin zur Behandlung von Wechseljahrsbeschwerden und gynäkologische 
Tumoren Anwendung findet. Ob Erythrina excelsa allerdings wirklich 
pharmakologisch aktive Substanzen enthält, die derartige Wirkungen erzielen 
können, wurde bisher noch nicht untersucht. Ecdysterone (Ecdy) ist ein Inhaltsstoff 
von verschiedenen Pflanzen, die in der chinesischen, ayurvedischen und russischen 
traditionellen Medizin zur Behandlung unterschiedlichster Beschwerden verwendet 
werden. Für Ecdy konnte eine anabole Wirkung in vitro und in vivo gezeigt werden. 
Obwohl die zugrunde liegenden Mechanismen noch nicht aufgeklärt sind, wird es 
intensiv als Nahrungsergänzungsmittel zur Steigerung des Muskelaufbaus beworben 
und auch von Bodybuildern verwendet. Ein Missbrauch zum Doping in anderen 
Sportarten wird befürchtet. Die Ziele dieser Arbeit waren zum einen die Bioaktivität 
von Extrakten von Erythrina excelsa, die in Bezug zur traditionellen Anwendung in 
der Naturmedizin stehen, sowie die biologisch aktiven Inhaltsstoffe in den Extrakten 
näher zu charakterisieren. Zum anderen sollten die Mechanismen der anabolen 
Wirkung von Ecdysterone untersucht werden. 
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Mittels Yeast Estrogen Screen (YES), uterotrophen Assay und des MTT-Assay 
konnte gezeigt werden, dass ein Äthanolextrakt von E. excelsa östrogene/anti-
östrogene und zytotoxische Effekte aufweist. Eine dreitägige subkutane 
Verabreichung des Extraktes in einer Dosis von 50 mg/kg KG/Tag an 
ovariektomierten Wistar Ratten führte zu signifikanten östrogenen Wirkungen auf 
morphometrische Parameter der Gebärmutter (Feuchtgewicht und epithelialen 
Höhen) und auf die Expression von Östrogen-abhängigen Genen in der Gebärmutter 
(C3 und Clusterin) und in der Leber (CaBP9K und IGFBP-1). Bei einer Dosis von 100 
mg/kg KG/Tag zeigte der Extrakt unerwartet auf die beschriebenen biologischen 
Endpunkte eine anti-östrogene Wirkung. Eine fünftägige Behandlung von 
Estrogenrezeptor (ER) -positiven MCF-7 Brustkrebszellen mit dem Extrakt führte zu 
einem biphasischen Profil: Bei niedrigen Konzentrationen kam es zu einem leichten 
Anstieg der Zellviabilität, bei höheren Konzentrationen dagegen zu einer Induktion 
von Zelltod. Dagegen wurde bei der Behandlung von ER negativen HT-29 Zellen 
Zytotoxizität bei allen getesteten Konzentrationen beobachtet. Um die Wirkstoffe des 
Extraktes näher zu charakterisieren, wurde eine Vakuum Flüssigchromatographie 
Fraktionierung durchgeführt. Biologisch aktive Fraktionen wurden mittels des YES 
Assays identifiziert  und die biologische Wirkung dieser Fraktion auf Proliferation und 
Apotose von MCF-7-Brustkrebs-Zellen mittels Durchflusszytometrie, 
Genexpressionsanalyse und Immunhistochemie untersucht. Die Dichloromethan-
Methanol (50:50 v/v) Fraktion (F4), die in Bezug auf östrogene und zytotoxische 
Wirkung die aktivste Fraktion war, zeigte eine nicht-monotone Konzentrations-
Wirkungs-Kurve auf den Zellzyklus, die Proliferation und Apoptose von MCF-7 
Brustkrebszellen. Bei niedrigen Konzentrationen und in Abwesenheit von E2, förderte 
F4 Östrogenrezenptor- abhängig die Proliferation von MCF-7 Zellen (Hochregulation 
von Cyclin D1 und Herunterregulation des Bax/Bcl-2-mRNA Verhältnisses). 
Interessanterweise wirkte F4 in den gleichen Konzentrationen bei Anwesenheit von 
E2, als Antagonist und verhinderte ein E2-induziertes Zellwachstum. Bei höheren 
Konzentrationen modulierte F4 den Zellzyklus zugunsten einer gesteigerten 
Apoptose (Erhöhung des Caspase-gespaltenen Zytokeratin 18, Hochregulation des 
Bax/Bcl-2 Verhältnisses und Herunterregulation von Cyclin-D1-mRNA). In 
Zusammenarbeit mit der Arbeitsgruppe von Dr. Halabalaki von der Abteilung für 
Pharmakognosie und Naturstoffchemie der Universität von Athen wurde eine weitere 
Zusammenfassung 
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Charakterisierung des Extraktes mittels LC-HRMS und LC-HRMS/MS Analyse 
durchgeführt um die im Extrakt enthaltenen Isoflavonoide zu identifizieren. Diese 
Analyse zeigte, dass Pyran- und Prenyl-Isoflavonoidderivate die charakteristischen 
chemischen Stoffe des Extrakts sind was auch die beobachtete Kombination der 
biologischen Eigenschaften des Extraktes erklären könnte. 
Im zweiten Teil dieser Arbeit  wurden die anabolen Wirkmechanismen von 
Ecdysterone, Erythrina excelsa Extrakt und Genistein in differenzierten C2C12 
Myoblasten, einem Zellkulturmodell für Skelettmuskelhypertrophie untersucht. Als 
untersuchter biologischer Endpunkt diente die Zunahme des Durchmessers von 
C2C12 Myotuben. Für die nähere Charakterisierung der involvierten molekularen 
Mechanismen wurden Studien mit Vergleichssubstanzen wie 
Androgenrezeptoragonisten (DHT), Androgenrezeptorantagonisten  (Flutamid), 
anabol wirkende Peptidhormone (IGF-1) und verschiedene Östrogenrezeptor 
bindende Substanzen mit agonistischen (E2), antagonistischen sowie ER alpha und 
ER beta selektiven Bindungseigenschaften verwendet. Mit diesem Modell konnten 
die wachstumsfördernden Wirkungen von IGF1, DHT, E2, Ecdy und des 
Phytoestrogens Genistein auf die Skelettmuskulatur bestätigt werden. Co-
Behandlung von Myotuben mit Ecdy und ZK führte zu einer  Hemmung der Ecdy-
induzierten Hypertrophie. Darüber hinaus führte auch eine Co-Behandlung von 
Myotuben mit E2 oder Ecdy und dem selektiven ER beta Antagonisten zu einer 
Antagonisierung der hypertrophen Wirkung von beiden Substanzen, was ein Zeichen 
von ERβ-abhängigem Effekt ist.  
Zusammenfassend zeigen die Befunde dieser Arbeit einerseits, dass der 
Extrakt von Erythrina excelsa biologische Effekte aufweist, die in engem 
Zusammenhang zu seiner traditionellen Verwendung stehen. Sie weisen auch darauf 
hin, dass diese Pflanze eine Quelle pharmakologisch aktiver Stoffe ist, die von 
potentiellem Interesse für weitere Untersuchungen sind. Darüber hinaus zeigen die 
Ergebnisse dieser Arbeit, dass Stoffe mit ER beta Bindungseigenschaften das 
Skelettmuskelwachstum fördern. Diese Erkenntnis ist von Interesse für die 
Behandlung von atropischen Erkrankungen des Skelettmuskels wie z. B der 
altersbedingten Abnahme der Muskelmasse (Sarkopenie). Allerdings kann dieser 
Zusammenfassung 
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Effekt auch zum Zwecke des Dopings missbraucht werden. Daher sind diese 
Befunde auch für die Ausgestaltung von Anti-Doping-Bestimmungen von Bedeutung. 
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Summary 
 
Medicinal plants serve as primary health care in most Asian and African 
countries. In developed countries where allopathic medicine is the most practiced 
form of medicine, chemicals of plant origin are increasingly consumed either as 
herbal formulations, diet, or complement to existing therapies in order to prevent or 
treat diseases. There is a general belief that because of their natural origin, herbal 
remedies are safe. Therefore they are commonly used in self therapeutic measures 
and are not prescribed in Germany. This work deals with the bioactivity and potential 
side effects of such herbal remedies. Namely the extract from Erythrina excelsa and 
the pure compound Ecdysterone were the focus of our attention. Erythrina excelsa is 
a plant used in the Cameroonian traditional medicine to alleviate menopausal 
symptoms and to treat female gynecological tumors. However, no test for biological 
activities evidencing these health benefit claims has been made so far. Ecdysterone 
(Ecdy) is the principal constituent of several plants used in the Chinese, Ayurvedic, 
and Russian traditional medicines to treat various ailments. Ecdy has been shown to 
exert anabolic properties in vitro and in vivo. Although the mechanisms underlying 
these effects are not yet elucidated, it is advertised as a food supplement to increase 
muscle mass and physical performance and is used by bodybuilders. A misuse for 
doping purpose in sports is suspected. The aims of this thesis were on the one hand 
to investigate the biological activities likely to explain the traditional use of Erythrina 
excelsa and to characterize its biologically active ingredients. On the other hand, this 
work also aims at examining the mechanisms underlying the anabolic effect of 
ecdysterone  
Using the yeast estrogen screen, the uterotrophic assay, and the MTT assay, 
we showed that an ethanol extract of E. excelsa exhibits estrogenic/anti-estrogenic 
and cytotoxic effects. A three-day subcutaneous administration of the extract at a 
dose of 50 mg/kg BW/day to ovariectomized Wistar rats produced significant 
estrogenic effects on uterine morphometric parameters (wet weight and epithelial 
height) and on the gene expression of estrogen responsive genes in the uterus (C3 
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and Clusterin) and in the liver (CaBP9K and IGFBP-1). Unexpectedly, at a dose of 
100 mg/kg BW/day the extract significantly decreased the same parameters below 
the control level indicating anti-estrogenic effects. The extract exhibited a biphasic 
profile on the growth of ER positive MCF-7 cells with a slight increase of cell viability 
at low concentrations and induction of cell death at higher concentrations. But on ER 
negative HT-29, cytotoxicity was observed at all concentrations tested. To get more 
insights into the active principles of the extract, a bioactivity-guided fractionation was 
performed and the bioactive fractions were identified by means of both YES and XTT 
assays. The effect of the most active fraction [Dichloromethane-Methanol (50:50, v/v) 
(F4)] on the proliferation and apoptosis of MCF-7 breast cancer cell line was 
assessed by flow cytometry, gene expression analysis and immunohistochemistry. 
F4 exhibited a non-monotonic concentration-response effect on the proliferation and 
apoptosis of MCF-7 breast cells. At low concentrations and in the absence of E2, F4 
promoted cell cycle progression through ER signaling and modulated gene 
expression in favor of cell survival (upregulation of cyclin D1 and and downregulation 
of the Bax/Bcl-2 ratio mRNA). Interestingly, when E2 was present, F4 at the same 
concentrations acted as an antagonist and prevented E2-induced cell growth. At 
higher concentrations, F4 modulated the cell cycle in favor of increased apoptotic cell 
death (increase of caspase cleaved cytokeratin 18, upregulation of Bax/Bcl-2 ratio 
and downregulation of cyclin D1 mRNA). In collaboration with the group of Dr. 
Halabalaki from the Department of Pharmacognosy and Natural Products Chemistry 
of the Unviversity of Athens, a LC-HRMS and LC-HRMS/MS analysis was performed 
to identify the isoflavonoids contained in the extract. This analysis showed that pyran 
and prenyl derivatives of isoflavonoids are the most characteristic chemical groups of 
the extract and may explain the observed biological activities. 
In the second part of this work, the mechanisms of the anabolic effect of 
ecdysterone, Erythrina excelsa extract and other plant secondary metabolites such 
as genistein were studied in a cell culture model of differentiated C2C12 myoblasts. 
This test system is a well established model to study the ability of anabolic 
substances to induce skeletal muscle hypertrophy as measured by the increase in 
the diameter of myotubes. Several comparative substances such as androgen 
receptor agonist (DHT) and antagonist (flutamide), anabolic peptide hormone (IGF-1), 
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and different estrogen receptor binding compounds with agonistic (E2), antagonistic 
(ZK), and ERα and ERβ selective binding properties were used for the 
characterization of the involved molecular mechanisms. With this model, we 
confirmed the skeletal muscle growth-promoting effects of IGF1, DHT, E2, Ecdy, and 
the phytoestrogen genistein. Co-treatment of myotubes with ZK and Ecdy led to an 
inhibition of Ecdy-induced hypertrophy. In addition, a co-treatment of myotubes with 
E2 or Ecdy and the selective ERβ antagonist prevented both substances to induce 
myotube hypertrophy, what unequivocally shows an ERβ-mediated effect. 
In general, the results of this work show that the extract of Erythrina excelsa 
has biological activities that are in close agreement with its reported traditional use to 
manage menopausal complaints and to treat female gynecological tumors. They also 
highlight the fact that this plant is a source of substances of potential interest for 
further pharmacological investigations. In addition, our findings also show that 
substances with ERβ binding affinity promote skeletal muscle growth and may 
provide new insights into therapeutic strategies for the treatment of skeletal muscle 
atrophic conditions such as the age-related decline in muscle mass (sarcopenia). 
However, this effect may be misused for doping purpose and is therefore also of 
importance for Anti-doping regulation.  
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1.1 Description of the research problem 
 
Most African and Asian countries have a long history of use of traditional 
medicine (TM) for health care. A World Health Organization (WHO) report shows that 
40-80% of the population in these countries rely on TM for primary health care 
(WHO, 2008). Traditional medicine is defined by the WHO as “diverse health 
practices, approaches, knowledge and beliefs incorporating plant, animal, and/or 
mineral based medicines, spiritual therapies, manual techniques and exercises 
applied singularly or in combination to maintain well-being, as well as to treat, 
diagnose or prevent illness“. In developed countries, TM is referred to as 
complementary and alternative medicine (CAM), non-conventional or parallel 
medicines. The use of TM/CAM has increased worldwide over the last decades. 
Surveys done in recent decades show that 20% of the EU-citizens have a clear 
preference for CAM healthcare, another 20% are regular users of CAM and more 
than 100 million citizens in the EU make use of CAM (EICCAM, 2009). The 
increasing use of TM/CAM raises some challenging issues concerning evidences on 
their quality, safety, and efficiency. The strategy of the WHO is to integrate TM/CAM 
into national health care systems. For this to occur, sufficient knowledge should be 
available on their efficiency or effectiveness and safety allowing the identification of 
safest and most effective therapies. TM also plays an important role in guiding drug 
discovery and development. Recent studies (Newman and Cragg, 2010; Cragg and 
Newman, 2013) analyzed the sources of new drugs over the period 01/1981-12/2010 
and reported that only 36% of 1073 new chemical compounds considered were 
devoid of natural inspiration as represented in Figure 1.   
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Figure 1:  Source of drugs (Adapted from (Cragg and Newman, 2013)). 
N: unmodified natural product; ND: Modified natural product; S: synthetic compound with no 
natural product conception; S*, S*/NM: Synthetic compound with a natural product 
pharmacophore, N/M indicating competitive inhibition; S/NM: synthetic compound showing 
competitive inhibition of the natural product substrate. 
Herbal medicine is one of the most used form of alternative therapy and is 
used either to prevent or to treat a wide range of health conditions (menopausal 
symtoms, fatigue, cardiovascular diseases, diabetes, cancer, mental disorder…). 
Erythrina excelsa Baker (Fabaceae/Leguminoseae) extract and Ecdysterone 
containing plants extracts such as Rhaponticum carthamoides, Achyranthes bidenta, 
and Trianthema portulacastrum are examples of herbal preparations that are used in 
several tradiotional medicine systems. E. excelsa is a plant belonging to the genus 
Erythrina that is known for its traditional use by several communities to treat a wide 
range of ailments (reviewed in Majinda et al., 2005). E. excelsa stem bark is reported 
to have been used by some village communities in the SouthWest region of 
Cameroon to alleviate menopausal complaints and to treat growths (uterine fibroids 
and ovarian cysts being the most frequent) in the female genital tract. Uterine fibroids 
are begnin growths that develop from the muscle tissue of the uterus. Normally they 
are not harmful but may under certain circumstances negatively affect fertility 
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outcomes (Pritts et al., 2009). It is recognized that 4-25 % of white women over 30 
years old are carriers of uterine fibroids, while this frequency increases to 50% in 
African women (Lefebvre, 1993). This shows that the use of this medicinal plant may 
include a population of both pre- and postmenopausal women. Like most herbal 
preparations used in the traditional medicine, testing for biological activity evidencing 
these health benefit claims has not been performed. Ecdysterone (Ecdy) also known 
as ecdisten, ecdysone, isoinokosterone, 20-hydroxyecdysone or β-ecdysterone 
belongs to the class of ecdysteroids that are steroids mainly found in Arthropods but 
that are also present in large amounts in certain plants including spinach (Spinacia 
oleracea). In vitro and in vivo studies have reported anabolic effects of Ecdy 
(Chermnykh et al., 1988; Gorelick-Feldman et al., 2008; Gorelick-Feldman et al., 
2010). However, despite these findings, the mechanisms by which Ecdy may exert 
this effect are not yet elucided. As a consequence of this lack of evidence, Ecdy is 
not subjected to regulation and is incorporated in many commercially available 
supplements for body-builders and sportsmen and may be misused for doping 
purpose.  
 
1.2 Aims and objectives of the thesis 
The aims and associated objectives of this thesis are : 
Aim 1: To evaluate the biological activities of E. excelsa in relation to its traditionally 
reported use for the management of menopausal complaints and for the treatment of 
female gynecological tumors. 
 
 To evaluate the estrogenic activity of an ethanol extract of E.excelsa; 
 To investigate the cytotoxic effect of E.excelsa ethanol extract. 
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Aim 2: To get more insights into the “active principles” of E. excelsa 
 To get a fraction containing the secondary metabolites accounting for the 
biological activities of interest (estrogenic and cytotoxic effects); 
 To evaluate the effect of this fraction on the growth of MCF-7 breast cancer 
cell line;  
 To identify the main chemical components of the extract. 
 
Aim 3: To elucidate the mechanisms by which the phytoecdysteroid Ecdysterone 
affect mammalian skeletal muscle homeostasis. 
 To evaluate the ability of Ecdysterone and other chamicals of plant origin to 
induce skeletal muscle hypertrophy; 
 To characterize the mechanisms invoved in the anabolic activity of 
Ecdysterone. 
Literature review 
M.Sc. Sadrine Tchoukouegno Ngueu  6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: LITTERATURE REVIEW 
Literature review 
M.Sc. Sadrine Tchoukouegno Ngueu  7 
 
 
Section 2.1: Estrogens 
 
There are three major naturally occurring estrogens (structures see below) in 
women. 17β-estradiol (E2) is the most potent and main estrogen found in 
premenopausal and non-pregnant women. After menopause estrone (E1) is 
predominant. Estriol (E3) is known as the pregnancy hormone.  
 
 
2.1.1 Synthesis and endogenous sources 
In premenopausal women, the ovaries are the primary site of production and 
source of circulating E2. The steroidogenic cells of the ovary are the granulosa cells 
that are the cellular compartment surrounding the oocyte and the theca cells that 
reside in the ovarian stroma (Havelock et al., 2004). The biosynthesis of estrogens in 
the ovaries is under the influence of the hypothalamic-pituitary axis and consists of 
the production of androgens from cholesterol in theca cells, followed by their 
conversion to estrogens in granulosa cells (Figure 2). The primary source of estrogen 
in postmenopausal women is from the conversion of androstenedione to estrone in 
adipose tissue. The placenta is the major source of estrogens during pregnancy.  
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Figure 2: Biosynthesis of estrogens in ovaries (Campbell reproductive biology July 2012: 
http://kcampbell.bio.umb.edu). SCC=P450scc= cholesterol side-chain cleavage enzyme; 3β-
HSD= 3β-hydroxysteroid dehydrogenase. The conversion of androstenedione to testosterone 
is mediated by the enzyme 17β- hydroxysteroid dehydrogenase (17β-HSD). 
 
2.1.2 Transport and metabolism 
In the circulation, most of the estrogen is reversibly bound to and transported 
by the sex hormone-binding globulin (SHBG). SHBG is a protein mainly secreted by 
the liver and it influences the action of the steroids in target tissue by regulating their 
bioavailability. Estrogens can also bind to albumin but with less affinity as compared 
to SHBG (17alpha-ethinylestradiol, the E2 derivate used for hormonal contraception, 
is almost exclusively bound to albumin). A small amount of estrogens circulate bound 
to HDL and LDL (Shwaery et al., 1997; Tang et al., 1997). 
Estrogens are mainly metabolized in the liver and the gastro-intestinal tract. 
They are conjugated in the liver as glucuronides, sulfates and thioether (Fishman et 
al., 1960; Tseng et al., 1972). The conjugated forms of estrogens are water soluble 
and are readily excreted via different routes (Eriksson and Gustafsson, 1971). The 
glucuronide conjugates are more rapidly excreted in urine than the sulfates that have 
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a higher chance to be hydrolyzed in tissues to biologically active estrogens 
(Sandberg and Slaunwhite, 1957). The estrogen metabolites that are excreted in the 
bile pass into the intestine, are hydrolyzed by intestinal bacteria (Adlercreutz et al., 
1976), and are either reabsorbed into the portal circulation or excreted in the feces.  
2.1.3 Mechanism of action 
2.1.3.1 Structure of estrogen receptors 
The biological effects of estrogens are mediated through two distinct estrogen 
receptors (ER) subtypes; ERα and ERβ that are members of the large superfamily of 
nuclear receptors. Like all other members of this family, ERs are composed of five 
independent but interacting functional domains (A/B-F). These domains are the N-
terminal domain (NTD or A/B), the DNA-binding domain (DBD or C), the hinge or D 
domain, the ligand-binding domain (LBD or E), and the F domain (Figure 3).  
The NTD or A/B encodes the transcriptional activation function (AF-1) (Kraus 
et al., 1995; McInerney and Katzenellenbogen, 1996) that is a region involved in the 
interaction with coregulator proteins. It can also be phosphorylated and thus is 
important for autonomous ligand-independent activation of transcriptional activity of 
the ER (Onate et al., 1998; Webb et al., 1998). This domain also comprises amino 
acids that are targets for post-translational modifications by kinases of growth factor 
pathways that stimulate the activation function 1 (AF-1) activity (Nilsson and 
Gustafsson, 2011) 
The DBD contains a zinc finger structure that plays an important role in the 
binding of the receptor to specific DNA sequences called estrogen response 
elements (ERE) (Beato, 1989; Schwabe et al., 1993).  
The D domain contains amino acid sequences that promote nuclear 
localization and those that are targets for post-translational modifications that affect 
ER activity and degradation (Nilsson and Gustafsson, 2011). It also serves as a 
flexible region connecting DBD and LBD (Kumar et al., 2011). 
The COOH-terminal or ligand-binding domain (LBD) is involved in ligand 
binding, receptor dimerization, and contains the ligand-dependent activation function 
2 (AF-2) that mediates the interaction of ERs with coregulator proteins and the 
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transactivation of target gene expression (Giguere et al., 1988; Danielian et al., 1992; 
Tsai and O'Malley, 1994; Henttu et al., 1997; Darimont et al., 1998; Feng et al., 1998; 
Shiau et al., 1998).  
The role of the F-domain in ER activity is not well defined, but some data 
suggest that this domain may affect the agonist/antagonist activity of selective ER 
modulators (SERMs), ER dimerization, and ER-coregulator interactions (Nilsson and 
Gustafsson, 2011).  
The two ERs share a quite high degree of sequence homology in their DBD 
(96% amino acid identity) and LBD (59% amino acid identity) (Nilsson and 
Gustafsson, 2011). However, the NTD of ERβ is shorter than that of ERα with a very 
poor sequence homology (Kumar et al., 2011). Moreover, the AF-1 domain of ERα is 
very active in the stimulation of reporter-gene expression from a variety of estrogen 
response element (ERE)-reporter constructs in different cell lines; while the 
transcriptional activity of the AF-1 of ERβ under the same conditions is negligible 
(Cowley and Parker, 1999).  
 
 
 
Figure 3: (A) Modular structure of nuclear receptors (Adapted from (Nilsson et al., 2001) and 
(B) protein sequence homology of the two ERs (Adapted from (Shao and Brown, 2004); 
percentages of homology are from Faulds et al. (2012). 
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2.1.3.2 Tissue distribution 
The two ER subtypes are expressed in both male and female reproductive and 
non-reproductive organs but show some differences in their tissue distribution (Figure 
4). In some organs, ERα and ERβ are co-expressed at similar levels, whereas in 
other tissues, one or the other subtype predominates (Nilsson and Gustafsson, 
2011). ERα is predominantly expressed in the uterus, prostate (stroma), ovary (theca 
cells), testes (Leydig cells), epididymis, bone, breast, liver, kidney, white adipose 
tissue, and various regions of the brain. ERβ is predominantly expressed in the 
intestine, prostate (epithelium), testis, ovary (granulosa cells), bone marrow, salivary 
gland, vascular endothelium, lung, bladder and certain regions of the brain (Ascenzi 
et al., 2006; Nilsson and Gustafsson, 2010). 
 
Figure 4: ERs distribution in male and female organs (Nilsson and Gustafsson, 2011) 
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2.1.3.3 Mechanism of estrogen action (Figure 5) 
Most of the effects of estrogens in target organs are exerted through the action 
of ERs on the gene expression (genomic actions), but a number of other effects are 
so rapid (within seconds or minutes) that they cannot depend on DNA transcription 
and protein synthesis (non-genomic actions). 
2.1.3.3.1 Genomic actions 
 Ligand-dependent mechanism 
 ERE-dependent pathway 
The ERE-dependent pathway is the classic/main mechanism through which 
the ERs modulate expression of target genes. In the absence of ligands, ERs are 
largely located in the cytosol where they are associated with intracytoplasmic 
chaperones such as heat-shock protein 70 and 90 (Smith et al., 1993). The binding of 
ligand causes the dissociation of the heat-shock proteins and the migration of the 
receptor to the nucleus where it dimerizes to either homodimers (ERα:ERα or 
ERβ:ERβ) or heterodimers (ERα:ERβ) and binds to ERE located in the promoter 
region of target genes (Nilsson et al., 2001). The binding of the ligand also induces a 
conformational change of the LBD that allows the recruitment of transcriptional 
cofactors (Rosenfeld and Glass, 2001). Two main categories of transcriptional 
cofactors can be distinguished: coactivators that activate target gene transcription, 
negative coregulators or corepressors that inhibit gene activation and possibly turn 
off activated target genes (Nilsson et al., 2001). 
 ERE-independent pathway 
The fact that around one third of the genes in humans that are regulated by 
ERs do not contain ERE-like sequences (O'Lone et al., 2004) has led to the 
subsequent discovery of signaling pathways that deviate from the classical model. In 
the ERE-independent signaling, ligand-bound ERs interact with other transcription 
factor complexes like fos/jun (AP-1-responsive elements) (Kushner et al., 2000) and 
SP-1 (GC-rich SP-I motifs) (Porter et al., 1997; Saville et al., 2000) that are already 
bound to their specific sites on DNA and influence the transcription of target genes 
whose promoters do not harbor EREs. The actions of ERs at SP-1 or AP-1 binding 
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sites (also called “tethering”) depend on the ligand, the cell type and the receptor 
subtype involved. 
 Ligand-independent mechanism 
In the absence of ligand, other signaling pathways can influence ER 
transcriptional activity either by directly targeting the receptor (through 
phosphorylation) or by regulating the activity of receptor coregulators. These 
signaling pathways include: 
-  Regulators of the general cellular phosphorylation state such as protein 
kinases A (PKA) (Aronica and Katzenellenbogen, 1993; Ince et al., 1994) and 
C (PKC) (Migliaccio et al., 1993; Lahooti et al., 1998); 
- Peptides Growth factors such as epidermal growth factor (EGF) (Ignar-
Trowbridge et al., 1992; Bunone et al., 1996), insulin-like growth factor (IGF-
1), and transforming growth factor alpha (TGF-α) (Ignar-Trowbridge et al., 
1996); 
- Neurotransmitters (dopamine) (Power et al., 1991; Smith et al., 1993); 
- Cell cycle regulators such as cyclin D1 (Neuman et al., 1997; Prall et al., 1998) 
and cyclin A (Trowbridge et al., 1997); 
- NF-κB (Chu et al., 2004; Mahmoodzadeh et al., 2009). 
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2.1.3.3.2 Non-genomic actions 
Apart from intracellular cellular ERs, membrane-associated ERs have been 
described and are thought to rapidly alter cellular physiology by activating G-protein 
coupled receptor (GPCR)-associated pathways. These non-genomic effects include: 
i) regulation of intracellular calcium homeostasis and mitogen-activated protein 
kinase (MAPK) pathway in different cell lines (Chen et al., 1999; Improta-Brears et 
al., 1999); ii) stimulation of adenylate cyclase activity and cyclic adenosine 
monophosphate (cAMP) production (Aronica et al., 1994); and iii) activation of the 
phosphoinositol 3-kinase (PI3k) signaling pathway (Chen et al., 1999; Castoria et al., 
2001; Marino et al., 2002).  
 
Figure 5: Molecular pathways of ERs actions (Heldring et al., 2007). TF= transcription factor; 
SM= second messenger. 
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2.1.4 Estrogens and health 
Estrogens play an important role in the growth and differentiation of the female 
reproductive organs that are also known as its classical targets. They are also 
involved in the function of several other tissues and organs including the 
cardiovascular and nervous systems, bone, skeletal muscle… 
2.1.4.1 Estrogens and hormone-dependent cancers 
Estrogens are crucial for the normal growth and development of reproductive 
organs.  
 Ovaries: estrogens have direct and indirect (through the pituitary gland) 
stimulatory effects on follicle growth. 
 Uterus: estrogens increase uterine weight through stimulation of fluid retention 
and hyperplasia of the cells of the endometrium, effects that prepare the 
uterus for implantation. They also induce the secretion of cervical mucus that 
facilitates the penetration of spermatozoa in the uterus. 
 Mammary tissue: estrogens are required for complete ductal elongation and 
branching, and the subsequent development of the lobulo-alveolar end buds 
(Brisken and Rajaram, 2006). 
 Vagina: estrogens stimulate the thickening, the stratification and keratinization 
of epithelial cells of the vagina. They also play an important role in the 
secretion of mucus that lubricates the vagina. 
However, animal studies using rodents have shown that estrogens can induce 
and promote mammary (Shull et al., 1997; Cavalieri et al., 2006), endometrial 
(Newbold et al., 1990) and other cancers (Kirkman, 1959; Bhat et al., 1993). 
Similarly, estrogens have been shown to promote tumor growth and the proliferation 
of cancer cells in vivo and in vitro. In humans, parameters such as early menarche, 
late menopause, short breastfeeding periods, and low number of pregnancies that 
maximize the number of ovulatory cycles and therefore the lifetime exposure to 
estrogens are associated with an increased risk of breast-cancer. Estrogens 
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supplementation in postmenopausal women is associated with an increased risk of 
breast and endometrial cancers.  
Two main mechanisms (Figure 6) are proposed to explain the carcinogenic effect 
of natural and synthetic estrogens: 
 Estrogens affect the rate of cell division and stimulate the proliferation of target 
cells via ER-mediated processes. This increased and abnormal cell 
proliferation can result in increased DNA damage leading to cancer if not 
repaired. It is also proposed that estrogens may act indirectly by enhancing 
the replication of cells carrying genetic errors (Nandi et al., 1995; Feigelson 
and Henderson, 1996; Dickson and Stancel, 2000; Hahn and Weinberg, 
2002). 
 
 Specific oxidative metabolites (catechol estrogen metabolites) of estrogens 
can react with DNA to cause mutations that may initiate cancer (Cavalieri et 
al., 1997; Cavalieri et al., 2000; Chakravarti et al., 2001; Cavalieri et al., 2004; 
Li et al., 2004; Zhao et al., 2006). 
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Figure 6: Mechanisms of estrogens-induced cancer 
 
2.1.4.5 Estrogen and skeletal muscle 
Estrogens are involved in the regulation of glucose metabolism in several 
tissues including skeletal muscles where they increase glucose uptake. Increasing 
evidences also show that estrogens modulate skeletal muscle mass and strength.  
Aging is associated with a decline in muscle strength and mass known as 
sarcopenia. However, there are gender differences in the age and rate at which 
Sarcopenia occurs. The prevalence of sarcopenia is higher among women than men 
and women exhibit an accelerated loss of muscle mass and strength at an earlier age 
(around the time of menopause)(Calmels et al., 1995; Dionne et al., 2000; Lemoine 
et al., 2003; Wiik et al., 2003). Imbalance between muscle protein synthesis and 
muscle protein breakdown is the major factor leading to sarcopenia (Short and Nair, 
2000). Increased oxidative stress and inflammation (Morley et al., 2001) and 
menopause-associated decline in hormonal levels (Maltais et al., 2009)  have also 
been shown to be implicated. Estrogens positively modulate skeletal muscle mass 
and strength (Lowe et al., 2010; Pollanen et al., 2011), decrease oxidative stress in 
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muscle (Lowe et al., 2010), and affect myosin function and composition (Kadi et al., 
2002; Moran et al., 2007). A recent study by Enns and Tiidus (Enns and Tiidus, 2010) 
suggested a gender and E2-specific influence on membrane and exercise-induced 
muscle damage. In the same line, Velders et al (2012) demonstrated that estrogens 
were able to regulate skeletal muscle growth and regeneration by stimulating 
anabolic pathways, activating satellite cells and modulating immune response. 
Both functional ERs isoforms are expressed in human skeletal muscle 
(Lemoine et al., 2003; Wiik et al., 2003; Wiik et al., 2009) and despite the recognized 
role of estrogens on muscle homeostasis, the mechanisms by which they exert their 
effects are not fully understood. Recent studies from our lab show that ERβ is the 
major ER isoform mediating estrogens effects on skeletal muscle growth and repair 
(Velders et al., 2012; Weigt et al., 2012). 
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Section 2.2: Phytoestrogens 
 
2.2.1 Definition and sources 
Phytoestrogens (PEs) are naturally-occurring plant compounds that are 
structurally and/or functionally similar to mammalian estrogens and their active 
metabolites. They are commonly divided into 4 groups: isoflavones (e.g. genistein, 
daidzein, glycitein, and formonetin), lignans (e.g. secoisolariciresinol, matairesinol, 
pinoresinol, and lariciresinol), coumestans (e.g. coumestrol), and stilbens (e.g. 
resveratrol) as presented in Figure 7. Lignans are found in many fiber-rich foods such 
as berries, seeds (particularly flaxseeds), grains, nuts and fruits (Nakamura et al., 
2007; Martin-Millan et al., 2010; Patisaul and Jefferson, 2010). Isoflavones are 
components of berries, wine, grains and nuts but are most abundant in soybeans and 
other legumes (Kurzer and Xu, 1997). Coumestans are found in many plants but 
especially in clover and alfalfa sprouts, and stilbens in grape-containing products, 
particularly red wine (Jefferson et al., 2012). 
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2.2.2 Absorption and metabolism 
Isoflavones and lignans are the two major classes of PEs in food and are the 
most studied and the best characterized with regard to PE metabolism. Genistein and 
daidzein, the predominant isoflavones, occur in soy mainly as biologically inactive 
glycoside conjugates (genistin and daidzin) (Patisaul and Jefferson, 2010). After oral 
ingestion, the glycoside conjugates are either hydrolyzed into their corresponding 
aglycones bioactive form (genistein and daidzein) by intestinal glucosidases or 
absorbed as conjugates. Genistein and daidzein can also be obtained from the 
intestinal hydrolysis of their respective precursor biochanin A and formonetin that are 
found in high amounts in red clover (Axelson et al., 1984). The aglycone metabolites 
Genistein Daidzein 
Enterolactone Enterodiol 
Coumestrol 
Resveratrol 
Isoflavones 
Lignans 
Coumestans 
Stilbens 
Figure 7: Major classes of phytoestrogens 
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are  further metabolized to more specific metabolites (p-ethylphenol for genistein, 
equol or O-desmethylangolensin for daidzein) (Axelson et al., 1984; Bannwart et al., 
1984; Kelly et al., 1993; Joannou et al., 1995). Once in circulation, PE undergo in the 
liver several other metabolic pathways including hydroxylation, glucuronidation, and 
sulfation (D'Alessandro et al., 2005). Then they are excreted in the urine or in the 
bile.  
Lignans exist in food as glycosides and are converted to enterolactone and 
enterodiol by the gut microflora (D'Alessandro et al., 2005). It is worth to note that the 
extent of PE metabolism and therefore the bioavailability of the active metabolites are 
highly variable among individuals and are influenced by many factors including the 
other components of the diet, gut microflora, use of antimicrobials, intestinal transit 
time, and genetic polymorphisms (Setchell et al., 1984; Messina et al., 2006). 
2.2.3 Mode and mechanisms of action 
Most PEs bind to ERα and ERβ and activate ER-dependent gene transcription 
through both ERs. However, unlike E2 that binds with equal affinity to both ERs, they 
bind predominantly to ERβ (Kuiper et al., 1997) and may exert both agonistic and 
antagonistic effects depending on the cellular context. Therefore, most PEs are 
termed as selective estrogen receptor modulators (SERMs). They have been 
reported to produce their effects either via direct binding to ER or by acting indirectly 
to modulate the concentration of endogenous estrogens. PEs modulate the brain-
pituitary-gonad axis which is the principal endocrine system to regulate mammalian 
reproduction. They induce changes in the concentration of circulating steroid 
hormones by inhibiting the secretion and activity of gonadotropin releasing hormone 
(GnRH) (Bowe et al., 2003; Christoffel et al., 2006; Losa et al., 2011), by increasing 
sex hormone binding globulin (SHBG) synthesis (Adlercreutz et al., 1987; Berrino et 
al., 2001), and through direct inhibition of some steroidogenic enzymes (Adlercreutz 
et al., 1993; Evans et al., 1995; Kao et al., 1998; Brooks and Thompson, 2005) .  
PEs may also induce effects that may not be mediated through ERs. For 
instance, the isoflavone genistein that is one of the most studied PE inhibited 
topoisomerase II (an enzyme involved in replication and transcription of DNA) in NIH 
3T3 cells (Okura et al., 1988). Several in vitro studies have also shown that genistein 
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inhibits the activity of tyrosine kinase which is essential for cellular growth and 
differentiation (Akiyama et al., 1987; Pagliacci et al., 1994; Dalu et al., 1998). 
Mutagenic (Kulling and Metzler, 1997; Mitchell et al., 2000; Misra et al., 2002) and 
antioxidant properties (Wei et al., 1993) of PEs have been described. Additionally, 
PEs exert non-genomic rapid effects for example through the binding of early 
intermediate genes such as jun and fos (Kushner et al., 2000). 
2.2.4 Phytoestrogens and health 
2.2.4.1 Phytoestrogens and the reproductive health 
The effects of PEs on female reproductive health depend on applied dose, 
route of exposure, and hormonal or developmental status of the exposed individual: 
different tissues have species-specific windows of sensitivity to morphological and 
functional disruption (Jefferson et al., 2012). Since Bennetts et al (1946) reported that 
sheep that grazed on red clover were infertile due to the estrogenic content in clover, 
several others have also reported on the impact of dietary PEs on the reproductive 
function in adults. There are limited available literature answering to this question 
with regard to the situation in humans but considerable studies have been performed 
in rodents. Perinatal PEs exposure in rodents is associated with an altered timing of 
puberty onset and estrous cyclicity as well as an abnormal development of the 
female reproductive tract (Kouki et al., 2003; Nikaido et al., 2004; Jefferson et al., 
2005; Bateman and Patisaul, 2008; Jefferson et al., 2012). 
2.2.4.2 Phytoestrogens and gynecological cancers 
Although weaker than natural estrogens, PEs mimic estrogenic effects on the 
reproductive organs. This raises some concerns because estrogens are implicated in 
the pathology of hormone-dependent cancers. However, epidemiologic studies show 
that Asiatic women have a significant lower incidence of hormone-dependent cancers 
compared to their age-matched Caucasian women and that this lower risk is 
positively correlated to PE consumption (Adlercreutz et al., 1992; Knight and Eden, 
1996; Setchell and Cassidy, 1999; Messina and Wood, 2008). This observation has 
motivated the scientific community to conduct intensive research that has 
unfortunately yielded heterogenic and contradictory results (probably because of the 
critical time-window of exposure). The impact of PEs on the incidence and 
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progression of reproductive cancer is controversially discussed and this controversy 
is fueled by the fact that apart from binding to ER and mimic estrogen effects, PEs 
have a plethora of other effects which are not yet fully understood. Moreover, as 
previously mentioned with regard to the impact on reproductive health, studies of our 
lab and other have revealed that the time of exposure to PEs is an important 
parameter to consider when evaluating breast cancer outcomes (Whitsett and 
Lamartiniere, 2006; Lee et al., 2009; Molzberger et al., 2012). Nevertheless, recent 
studies report beneficial effects of PE consumption on gynecological cancer risk. In a 
3 years randomized controlled trial (RCT), Palacios et al (2010) assessed the effects 
of an oral soy isoflavone extract (Phytosoya 70 mg daily dose) on the endometrium 
and breast of 395 postmenopausal women and found no increase in endometrial and 
breast cancers. Steinberg et al (2011) demonstrated that 403 healthy 
postmenopausal women that received a daily isoflavone dose of 80-120 mg for one 
year showed no significant difference in endometrial thickness or fibroids. In the 
same line, Ollberding et al (2012) found a reduced risk of endometrial cancer 
associated with total isoflavone, daidzein or genistein intake after 13.6 years follow 
up of 46027 non hysterectomized postmenopausal women. Myung and coworkers 
(Myung et al., 2009) also showed a protective effect of soy intake on the risk of 
ovarian cancer. The possible actions of phytoestrogens in relation to cancer are 
presented on Figure 8.  
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Figure 8: Overview of possible actions of phytoestrogens in relation to cancer (adapted from 
(Mense et al., 2008)). 
 
2.2.4.3 Phytoestrogens and menopausal symptoms 
Despite intensive investigations on the effects of PE on the vasomotor 
symptoms of menopause (mainly hot flushes), it remains unclear whether PEs are 
clinically relevant for the management of these disorders. Bolanos and coworkers 
(2010)  recently performed a systematic review and meta-analysis of 90 randomized 
controlled trials (RCT) to determine whether soy intervention either as diet, extract or 
concentrate reduces the incidence of hot flashes in climacteric women. They found a 
significant tendency in favor of soy ISO but were not able to establish conclusive 
results due to the high heterogeneity found in the studies. Following a similar 
exercise, Howes et al (2006) concluded that soy supplementation may produce a 
slight to modest reduction of the number of daily flushes. 
The impact of PEs, particularly ISO, on the cardiovascular health is also 
controversially discussed with some studies reporting beneficial effects and others no 
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effect. Hypercholesterolemia is a well-documented and established risk factor for 
coronary heart disease and soy proteins but not purified isoflavones have been 
shown to lower serum cholesterol levels (Nagata et al., 1998; Dewell et al., 2006). 
 Several randomized placebo-controlled trials have been performed to 
determine the effect of oral ISO supplementation on endothelial function as 
measured by flow-mediated dilatation (FMD) in postmenopausal women. In a meta-
analysis of 9 of such trials, Li et al (2010) found that oral ISO supplementation does 
not improve endothelial function in postmenopausal women with high baseline FMD 
levels but leads to signiﬁcant improvement in women with low baseline FMD levels. 
Bone cell culture and the rat model of postmenopausal osteoporosis have 
been extensively used to show that PE can prevent postmenopausal bone loss (Lee 
et al., 2004; Hertrampf et al., 2007). Setchell and lydeking-Olsen (2003) compared 
data from 17 studies on cultured bone cells, 24 studies of animal model for 
postmenopausal osteoporosis, 15 human observational/epidemiological studies, 17 
dietary intervention studies and found that diets rich in PE have bone-sparing effects 
in the long-term. Yamori et al (2002) came to the same conclusion after an 
intervention study performed with immigrants Japanese women in Brazil.  
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Section 2.3: Erythrina excelsa Baker 
 
2.3.1 Taxonomy 
Kingdom: Plantae 
Phylum: Magnoliophyta 
Class: Magnoliopsida 
Order: Fabales 
Family: Fabaceae, Leguminosae, 
Genus: Erythrina 
Botanical names: Erythrina bagshawei Baker F., Erythrina seretii De Wild, Erythrina 
excelsa Baker 
 
 
Figure 9: Erythrina Excelsa (April 2011 in Kumba-Cameroon by Stephane Zingue) 
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2.3.2 Description and geographical distribution 
The genus Erythrina comprises around 110 species of orange or red flowered 
trees, shrubs and herbaceous plants found throughout tropical and semi-topical 
regions of the World. These species are distinguished based on their morphology 
mainly the color and shapes of the flowers and fruits, and the inflorescence 
characteristics (Majinda et al., 2005). E. excelsa is a deciduous medium sized tree of 
up to 30m tall that grows very fast and usually flowers when leafless. The 
inflorescence of E. excelsa is compact, axillary or terminal. The flowers are bisexual, 
papilionaceous with a spathe-like, glabrous or slightly hairy calyx that is splitted at 
one side. The corolla is orange-red to scarlet or coral-red. The fruit is a linear-oblong 
spirally twisted pod markedly constricted between the orange-red with whitish scar 
seeds (up to 10/fruit) (Lemmens, 2008). E. excelsa is mainly found in the Democratic 
Republic of Congo, Cameroon, Ivory Coast, Mali, Southern Nigeria, Sudan, and 
throughout East Africa except Zanzibar. 
2.3.3 Active constituents of plants of the genus Erythrina 
Several secondary metabolites have been reported : alkaloids, flavanones, 
flavonols, chalcones, cinnamoyl phenols, stilbenoids, isoflavones, isoflavans, 
isoflavanones, pterocarpans, isoflav-3-enes, 3-phenoxychromones, coumastans, 3-
phenylcoumarins, lignans, cinnamate esters, simple phenolics, triterpenes, 
sesquiterpenes, squalene, C-18 unsaturated hydroxycarboxylic acid, and 
octacosanol (Majinda et al., 2005). Previous phytochemical studies reported the 
isolation of a long chain ester of ferulic acid (Wandji et al., 1990) and a prenylated 
isoflavonoid (Tanee Fomum et al., 1986) from E. excelsa. 
2.3.4 Traditional uses of Erythrina excelsa Baker 
The wood of E. excelsa is popular in Uganda for making drums, stools, 
shields, mortars and carving for the tourist industry. It is also used as fuel wood and 
for making charcoal (Lemmens, 2008). As in Uganda, E. excelsa is planted in 
Cameroon as an ornamental and roadside tree. 
Some village communities in the South West region of Cameroon reported the 
use of E. excelsa for the management of menopausal complaints and for the 
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treatment of growths in the female genital tract (ovarian cysts and uterine fibroids). 
Others have also reported the use of E. excelsa as an antidote for snakebites (Owuor 
and Kisangau, 2006; Lemmens, 2008; Samy et al., 2008) and for arthritis and catarrh 
(Jiofack et al., 2010). 
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Section 2.4: Ecdysterone 
 
2.4.1 Origin and sources 
Ecdysterone (Ecdy) (Figure 10) belongs to the large family of ecdysteroids that 
are polyhydroxylated hormones found in arthropods. Several plant species 
synthesize ecdysteroids and there were more than 300 reported phytoecdysteroids in 
2008 (Bathori et al., 2008). Some of these ecdysteroids containing plants are 
included in the human diet (spinach) and are used in several traditional medicine 
systems for the treatment of various ailments. For example: 
- Rhaponticum carthamoides is used in the Siberian traditional medicine 
in cases of overstrain and common weakness after illness (Petkov et 
al., 1984); 
- Achyranthes bidentata is used in Chinese traditional medicine for the 
treatment of osteoporosis (Zhang et al., 2012); 
- Trianthema portulacastrum is  used in Ayurvedic traditional medicine as 
analgesic, laxative and for the treatment of blood diseases, anemia, 
inflammation, and night blindness (Shivhare et al., 2012). 
 
Figure 10: 20-hydroxyecdysone (20 HE) or Ecdysterone 
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2.4.2 Biological effects 
In plants, phytoecdysteroids act as protective agents against predatory insects 
(Le Bizec et al., 2002). In insects, ecdysteroids exert trophic effects on muscles and 
play an important role in metamorphosis (hence the name molting hormone) 
(Schwartz and Truman, 1984). This muscle growth stimulatory effect of ecdysteroids 
has inspired several research activities to test whether they could produce the same 
effect in vertebrates and mammals in particular. 
In vitro and in vivo experimental models have shown that Ecdy exhibits 
anabolic effect on mammalian skeletal muscles. Ecdy has been demonstrated to 
increase protein synthesis in skeletal muscle (Chermnykh et al., 1988) and in other 
organs (Otaka et al., 1968; Chaudhary et al., 1969; Otaka et al., 1969; Hikino and 
Takemoto, 1972; Syrov and Kurmukov, 1976). Gorelick et al (2008; 2010) using 
cultured murine C2C12 myotubes showed that this increased protein synthesis was a 
result of direct or indirect stimulation of the PI3K/Akt signaling pathway as indicated 
on Figure 11. 
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Figure 11: Pathways of Ecdysterone-induced protein synthesis in skeletal muscle (Gorelick-
Feldman et al., 2010). 20HE: 20-hydroxyescdysone; PIP2: phosphatidylinositol-4,5-
diphosphate; PLC: phospholipase C; IP3: Inositol-1,4,5-triphosphate; IP3R: IP3 receptor; SR: 
sarcoplasmic reticulum. 
 
Toth et al (2008) showed that treatment of adult non-castrated male Wistar 
rats for 7 consecutive days with 5 mg/kg BW Ecdy leads to an increase of the fiber 
size of both soleus and extensor digotorum longus (EDL) muscles. They proposed 
that this increase may involve the activation of satellite cells as they found that the 
number of nuclei also increased in Ecdy treated animals. 
To date, it is not clear whether Ecdy exerts the same effects in humans 
although ecdysteroids were reported as being  used by athletes in Asian countries 
(Bathori et al., 2008) and by Russian Olympic athletes (Le Bizec et al., 2002). Schoch 
et al (2006) investigated the effect of 8 weeks Ecdy supplementation on body 
composition, markers of catabolism (creatinine, creatine kinase, lactate 
deshydrogenase...), and on training adaptation of 45 resistance-trained males and 
found no effect on the parameters considered.  
Literature review 
M.Sc. Sadrine Tchoukouegno Ngueu  32 
 
Conversely to anabolic-androgenic steroids (AAS) that increase muscle mass 
mainly through their binding to androgen receptor (AR), no nuclear receptor that is 
homologous to the ecdysone nuclear receptor (EcR) found in insects have yet been 
described in mammals (Gorelick-Feldman et al., 2010). Ecdysterone has been 
characterized as devoid of binding ability to either AR (Bathori et al., 2008; Gorelick-
Feldman et al., 2008), ER (Bathori et al., 2008; Seidlova-Wuttke et al., 2010), or 
glucocorticoid receptor (Bathori et al., 2008). Therefore, the mechanisms underlying 
the action of Ecdy in mammals are still to be clarified. 
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Section 2.5: Marker genes used 
 
The molecular markers for estrogenicity/cytotoxicity used in this work are 
described in the following paragraphs. 
2.5.1 Complement component 3 (C3) 
The C3 gene encodes for a protein called complement component 3 that plays 
a key role in a part of the body´s immune system known as complement system. 
Together with other proteins of the complement system, C3 triggers inflammation, 
serve as a first line of defense against infection, and acts to bridge the innate and the 
adaptive immune system (Carroll and Prodeus, 1998; Barrington et al., 2001). The 
C3 gene is constitutively expressed in the liver and its up-regulation in the uterine 
endometrium following estrogen administration has been extensively demonstrated 
(Diel et al., 2004; Hofer et al., 2009; Kluxen et al., 2012). 
2.5.2 Clusterin 
Clusterin, also known as testosterone-repressed protein message 2 (TRPM2), 
Apolipoprotein J (ApoJ), or sulphated glycoprotein 2 (SGP-2), is a 75-80 kDa 
heterodimeric glycoprotein produced by a wide array of tissues and found in most 
biological fluids. Based on its distribution and in vitro properties, several physiologic 
functions have been proposed and include complement regulation, lipid transport, 
sperm maturation, initiation of apoptosis, endocrine secretion, membrane protection, 
and promotion of cell interactions (Rosenberg and Silkensen, 1995). Estrogen-
dependent regulation of the clusterin mRNA-expression has been reported in rat 
uterus (Diel et al., 2000) and in endometrial estrogen-dependent carcinoma 
(Wunsche et al., 1998). 
2.5.3 Insulin-like growth factor binding protein 1 (IGFBP-1) 
IGFBP-1 mRNA and protein expression have been identified in human liver, in 
uterine decidua, and in nonhuman kidney. It is one of the six structurally homologous 
proteins that specifically bind and modulate the mitogenic and metabolic actions of 
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insulin-like growth factor (IGF)-I and IGF-II (Lee et al., 1993). It has been shown in 
vitro (Diel et al., 1995), in vivo (Geis et al., 2005), and in humans (Isotton et al., 2012) 
that estrogens up-regulate IGFBP-1 expression.  
2.5.4 Vitamin D dependent calcium binding protein 9kDa (CaBP9K) 
CaBP9k or calbindin-9k is a member of a large family of intracellular calcium 
binding proteins that have high affinity for calcium (Kim et al., 2012). It plays an 
important role in calcium transport and re-asorbtion in many tissues (Wasserman and 
Taylor, 1966; Bruns et al., 1988; Balmain, 1991; Krisinger et al., 1994). Diel et al 
(1995) identified CaBP9k as an estrogen regulated gene in Fe33 rat hepatoma cells. 
The CaPB9k promoter contains several EREs (Lee et al., 2003). 
2.5.5 Cyclin D1 (CCND1) 
Cyclin D1 together with other members of cyclins family regulate progression 
through the cell cycle leading to mammalian cell division. Upon binding to cyclin 
dependent kinases Cdk4 and Cdk6, CCND1 phosphorylates the retinoblastoma 
protein (Rb) and promotes the transition from G1 to S phase. CCND1 gene is 
amplified in 15% of primary ER positive breast cancers and is overexpressed in up to 
50% of cases (Tobin and Bergh, 2012). Although there is no classical ERE in the 
CCND1 promoter (Liu et al., 2002), estrogens when bound to ER (ERα) are able to 
upregulate CCND1 mRNA expression (Liu et al., 2002; Tobin and Bergh, 2012). On 
the other hand, CCND1 has been shown to directly interact with the LBD of ER and 
to stimulate ER transactivation in a ligand-independent fashion (Zwijsen et al., 1997) 
2.5.6 Bax 
Bax belongs to the proapoptotic members of the Bcl-2 family of proteins whose 
role in the regulation of apoptotic cell death is well characterized. It is a soluble 
monomeric protein that is localized in the cytosol or is attached at the periphery of 
intracellular membranes in unstimulated cells (mitochondria, endoplasmic reticulum, 
and nucleus) (Goping et al., 1998; Danial, 2007). Upon a death stimulus, Bax is 
activated and translocates to the outer mitochondrial membrane where it promotes 
the release of cytochrome C from the mitochondria. Once released, cytochrome C 
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activates a caspase cascade leading to increased mitochondrial mediated apoptotic 
cell death (Adams and Cory, 1998). 
2.5.7 Bcl-2 
Bcl-2 is the prototype protein of the BCL-2 family and was first discovered as a 
proto-oncogene in follicular lymphoma (Tsujimoto et al., 1984). It codes for an 
antiapoptotic protein that acts by binding and antagonizing the proapoptotic effectors 
Bax and Bak (Carpinelli et al., 2012). Bcl-2 protein is overexpressed in a variety of 
solid organ malignancies including breast cancer (Dawson et al., 2010). Estrogens 
have been shown to prevent apoptosis of normal and breast tumor cells through the 
activation of Bcl-2 gene expression (Somai et al., 2003).  
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3.1 Material 
 
3.1.1 Substances 
The following substances were used either as test substance or positive 
control: 
 
Substances Chemical structure Manufacturer 
1. 17β-Estradiol or E2 
(Estra-1,3,5(10)-trien-
3,16α,17 β-diol)  
 
Sigma-aldrich 
(Steinheim, Germany) 
2. Genistein (Gen) (4´,5,7-
Trihydroxyisoflavon)  
 
LC Laboratories 
(Wolburn, USA) 
3. ERα-selective agonist 
or ALPHA [(16α-LE2), 
3,17-dihydroxy-19-nor-
17α-pregna-1,3,5 (10)-
triene-21,16α-lactone;)]  
 
Bayer HealthCare 
Pharmaceuticals 
(Berlin-Germany) 
4. ERβ-selective agonist 
or BETA [(8β-VE2), 8-
vinylestra-1,3,5 (10)-
triene-3,17ß-diol]  
 
Bayer HealthCare 
Pharmaceuticals 
(Berlin-Germany) 
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5. ZK 283361 (ERβ 
antagonist or Anti-BETA) 
 
Bayer HealthCare 
Pharmaceuticals 
(Berlin-Germany) 
6. 20-Hydroxyecdysone or 
Ecdy ( 
2β,3β,14α,20β,22,25-
Hexahydroxy-7-cholesten-
6-one) 
 
Sigma-aldrich 
(Steinheim, Germany) 
7. Cisplatin (cisplatinum, 
or cis-
diamminedichloroplatinum) 
 
Millipore (Darmstadt, 
Germany) 
8. ZK 191703 or ZK (pure 
antiestrogen ) 
  
Bayer HealthCare 
Pharmaceuticals 
(Berlin-Germany 
9. Dihydrotestosterone 
(DHT) 
 
Sigma-aldrich 
(Steinheim, Germany) 
10. Flutamide (Flu) 
 
Sigma-aldrich 
(Steinheim, Germany) 
11. LONG®R3 IGF-1, 
human recombinant 
analog (IGF-1)   
Sigma-aldrich 
(Steinheim, Germany) 
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3.1.2 Chemicals, consumables and lab equipments 
 
Table 1: List of chemicals 
Chemicals Manufacturer 
Yeast growth and assay media components 
Adenine Sigma-aldrich (Steinheim, Germany) 
CuSO4 _ 
CPRG 
Roche diagnostics (Mannheim, 
Germany) 
Fe2(S04)3 Merck (Darmstadt, Germany) 
KH2PO4 _ 
KOH _ 
L-arginine-HCI Sigma-aldrich (Steinheim, Germany) 
L-aspartic acid _ 
L-glutamic acid _ 
L-histidine _ 
L-Ieucine _ 
L-isoleucine _ 
L-lysine-HCl _ 
L-methionine _ 
L-phenylalanine _ 
L-serine _ 
L-threonine _ 
L-tyrosine _ 
L-valine _ 
MgSO4 _ 
(NH4)2S04 Merck (Darmstadt, Germany) 
Pantothemic acid Sigma-aldrich (Steinheim, Germany) 
Pryridoxine _ 
Thiamine _ 
Inositol _ 
Biotin _ 
D-(+)-glucose Merck (Darmstadt, Germany) 
Buffers components 
Na2HPO4 *2H2O Merck (Darmstadt, Germany) 
NaCl _ 
NaH2PO4* H2O _ 
NaOH _ 
Tris _ 
Triton X 100 Sigma-aldrich (Steinheim, Germany) 
Tween 20 Sigma-aldrich (Steinheim, Germany) 
Sucrose  
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Bromophenol blue Merck (Darmstadt, Germany) 
Xylene cyanol _ 
HCl (1M) _ 
NaOH (1M) _ 
EDTA Sigma-aldrich (Steinheim, Germany) 
Glacial acetic acid  Merck (Darmstadt, Germany) 
PMSF  
 Sodium deoxycholate 
  
Protein analysis 
BSA PAA Laboratories (Pasching, Austria)  
Milk powder Reformhaus Bacher (Cologne, Germany) 
SDS-loading buffer (Laemmli 1970) BIO-RAD (Munich, Germany) 
NuPAGE Novex 4–12% Bis–Tris Midi Gel  Invitrogen, life technologies 
DC protein assay reagent A BIO-RAD (Munich, Germany) 
DC protein assay reagent B _ 
Precision Plus Protein™Dual color Standards _ 
  
Cell culture media components 
DMEM Gibco, Invitrogen (Karlsruhe, Germany) 
Glutamin _ 
FBS _ 
Horse serum _ 
Human insulin _ 
PBS cell culture grade _ 
Penicillin-Steptomycin _ 
Trypsin-EDTA (0.05%) _ 
RPMI 1640 _ 
Sodium bicarbonate _ 
Sodium pyruvate _ 
Freezing medium _ 
  
PCR reaction components 
dNTPs Invitrogen, life technologies (Karlsruhe, Germany) 
PCR buffer _ 
MgCl2 for PCR _ 
Taq polymerase _ 
Ampuwa _ 
Primers _ 
  
RNA preparation 
TRIzol ®reagent Invitrogen, life technologies (Karlsruhe, Germany) 
Chloroform Merck (Darmstadt, Germany) 
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Isopropanol _ 
EtOH for molecular biology _ 
DEPC  
Nucleic acids electrophoresis and staining dyes 
DAPI Sigma-aldrich (Steinheim, Germany) 
Propidium iodide (PI) _ 
Ethidium bromide _ 
Sybr Green BIO-RAD (Munich, Germany) 
Agarose Biozym  (Hess. Oldendorf, Germany)  
100 bp DNA ladder Invitrogen, life technologies (Karlsruhe, Germany) 
Kits 
MTT Roche diagnostics (Mannheim, Germany) 
XTT Roche diagnostics (Mannheim, Germany) 
QuantiTect® Reverse transcription Qiagen 
  
Other Organic solvents 
EtOH for histology  
MeOH Merck (Darmstadt, Germany) 
MeOH HPLC grade VWR (Leuven,Belgium) 
Cyclohexane HPLC grade _ 
Dichloromethane HPLC grade _ 
Xylol Quadflieg (Geselkirchen, Germany) 
DMSO Merck (Darmstadt, Germany) 
Formaldehyd 37% _ 
  
Others 
Paraffin Sasol wax (Hamburg, Germany) 
Corn oil Sigma-aldrich (Steinheim, Germany) 
Glutardialdehyde Merck (Darmstadt, Germany) 
Activated carbon _ 
Meliseptol B. Braun (Melsungen, Germany) 
Liquid nitrogen Air Liquide (Düsseldorf, Germany) 
Eosine VWR (Leuven,Belgium) 
Mounting medium (Entellan®) Merck (Darmstadt, Germany) 
Mayer Hamalun _ 
Silicagel (60 Å, 70-230 mesh)  Sigma-aldrich (Steinheim, Germany) 
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 Antibodies  
Table 2:  List of antibodies 
Antibody Host Dilution  Manufacturer 
Primary antibodies 
Anti-β-actin(clone AC-74) mouse 1:5000 Sigma-aldrich  
Anti-ERβ (H-150) rabbit 1:200 
Santa Cruz Biotechnology, 
Inc  
M30 CytoDEATH mouse 1:10 Roche Applied Science 
secondary antibodies  
Anti-Mouse Ig, HRP* rabbit 1:2000 Dako 
Anti-Rabbit Ig, HRP Swine 1:2000 Dako 
Anti-Mouse Ig biotinylated Goat 1:400/1:200 Dako 
signal detection reagents 
chemoluminescent POD-
Substrate (LumiLight Plus)   
Roche Diagnostics  
FluoroLinkTM Cy3 labelled 
streptavidin    1:1000 
Amersham Biosciences 
* Horseradisch peroxidase 
 
Table 3: Consumables and equipement. 
Consumables and equipments Manufacturer 
42ippsipette tips 1 – 5mL _ 
Eppendorf Tubes  Eppendorf (Essling-Berzdorf, Germany) 
RT-qPCR plates 96-well plates without border 
QPCR 
Agilent Technologies (Waldbronn, 
Germany) 
Optical Cap Mx3000P/Mx3005P 8 x Strip _ 
Falcon tubes 15 mL BD Biosciences(Heidelberg, Germany) 
Falcon tubes 50 mL BD Biosciences(Heidelberg, Germany) 
Gloves Comfort Unigloves (Troisdorf, Germany) 
Gloves Nitrile VWR (Leuven,Belgium) 
Syringes Injekt solo 2-10 mL B. Braun (Melsungen, Germany) 
Sterile syringue filter 0.2 μm VWR (Leuven,Belgium) 
Cannulas 0.6 x 30 mm HenrySchein (Melville NY, USA) 
Towels facial tissues Flirty H.-Kimberly (Mainz, Germany) 
Coverslips Coverslips 50x30 mm VWR (Leuven,Belgium) 
Polysine slides _ 
Embedding cassette Histosette  _ 
pH meter  Mettler Toledo (Giessen, Germany) 
Cell scraper BD Biosciences(Heidelberg, Germany) 
Protran®Nitrocellulose Membranes Whatman Inc (USA) 
96-well optically flat bottom plates Nunc (Danemark) 
96-well optically round bottom plates BD Biosciences(Heidelberg, Germany) 
6-well plates _ 
Chromatography column NS 14/23 Lenz Laborglas GmbH & Co. kG 
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(Wertheim, Germany) 
Ice Machine, AF 80 Scotsman (Milan, Italy) 
Freezer (-20 °C) Liebherr (Bulle, Switzerland) 
Freezer (-80 °C) HERAfreeze Heraeus ( Hanau, Germany) 
Gel chamber small or medium Biometra (Göttingen, Germany) 
Camera and evaluation system for agarose gels MWG-Biotech (Ebersberg, Germany) 
Refrigerator Liebherr (Bulle, Switzerland) 
Refrigerated Centrifuge Centrifuge 5417 R Eppendorf (Essling-Berzdorf, Germany) 
Microwave  MS192A LG (Willich, Germany) 
PCR GeneAmp PCR system 9600 Applied Biosystems (Foster City, USA) 
Pipettes Eppendorf (Essling-Berzdorf, Germany) 
RT-qPCR Stratagene Mx3005P Agilent Technologies  
Spectrophotometer NanoDrop 1000 
Thermo Fisher Scientific (Schwerte, 
Germany) 
Benchtop centrifuge Biofuge 13 Heraeus (Hanau, Germany) 
Vortex Genie 2 Scientific Industries (Bohemia NY, USA) 
Libra Scaltec SBA52 Denver Instrument (Göttingen, Germany) 
Inverted microscope Axiovert 200M Zeiss (Jena, Germany) 
Confocal microscope Axiophot KS300  Zeiss (Jena, Germany) 
Microscope Camera (3 CCD  colr video camera) Sony (Tokio, Japan) 
Microscope Camera B / W HAL 100  Zeiss (Jena, Germany) 
Microtome Autocut Mod 1140  Reichert-Jung (Vienna, Austria) 
Oven T5052 E  Heraeus ( Hanau, Germany) 
Embedding centre  MPS/P2  Slee  (Mainz, Germany) 
Microplate Reader MWG-Biotech (Ebersberg, germany) 
XCell4 SureLock™ Midi-Cell electrophoresis 
system  Invitrogen ( Karlsruhe, Germany) 
Trans-Blot®Turbo™ Transfert System BIO-RAD (Munich, Germany) 
BD FACSCalibur flow cytometer  BD Biosciences (USA) 
Elisa reader  
Thermoscientific (Lagenselbord- 
Germany) 
CO2 incubator C 150 Binger GmbH (Tuttligen, Germany) 
Waterbath Kottermann (Vienna, Austria) 
Ultrospec 2000 (UV/visible spectrophotometer) Pharmacia Biotech 
SANYO Incubator MIR 152 SANYO Electric Co.Ltd (Japan) 
Microplate shaker VWR (Leuven,Belgium) 
Autoclave Systec GmbH (Wettenberg, Germany) 
HeraSafe biological safety cabinet Heraeus ( Hanau, Germany) 
HPLC  system  Thermo Finnigan, San Jose, CA 
UHPLC system 
Thermoscientific (Lagenselbord- 
Germany) 
LTQ-Orbitrap Mass Spectrophotometer _ 
LTQ-Orbitrap Mass Spectrophotometer  _ 
Hypersil Gold column (100 x 2.1 mm id, 3µm 
particle size) _ 
Discovery Supelco HS C-18 column (25 x 4.6 
mm, 5µm particle size) Sigma-aldrich (Steinheim, Germany) 
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3.1.3 Test organisms 
3.1.3.1 Animals 
Juvenile female Wistar rats aged 5 weeks and weighing 101-124 g were 
obtained from Janvier (Le Genest St Isle, France). They were maintained under 
controlled temperature (20±1°C), humidity (50-80%), and illumination (12h light, 12h 
dark) conditions. The rats had free access to standard rat soy free diet (Sniff R10-
Diet, Ssniff GmbH, Soest Germany) and water. All animal handling and experimental 
conditions were carried out according to the Institutional Animal Care and Use 
Committee guidelines regulated by the German federal law for animal welfare. 
3.1.3.2 Yeast strain 
Yeast cells (saccharomyces cerevisiae) originated from Glaxo. They are stably 
transfected with the human estrogen receptor alpha (hERα) gene, together with 
expression plasmids containing estrogen-responsive elements and the lac-Z reporter 
gene encoding the enzyme β-galactosidase. 
3.1.3.3 Cell lines 
 MCF-7  
 MCF-7 cells are immortalized cells from human breast adenocarcinoma that 
were isolated in 1970 from a 69 year-old Caucasian woman. They grow as an 
adherent monolayer in cell culture flasks and have retained several characteristics 
particular to the mammary epithelium. Moreover, estrogens can activate the ER 
found in their cytoplasm and they are known as ER positive cell line. MCF-7 cells are 
useful for in vitro breast cancer studies and were kindly provided by Bayer 
HealthCare Pharmaceuticals (Berlin, Germany).  
 HT-29 
 HT-29 cells were isolated in 1964 from a primary adenocarcinoma of a 44 
year-old Caucasian woman. They grow as adherent monolayer and are able to 
express differentiation features that are characteristic of mature intestinal cells. Apart 
from their particular use in glucose metabolism and hormones receptors studies, they 
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are like all other cancer cell lines used in the area of cancer research. They were also 
provided by Bayer HealthCare Pharmaceuticals. 
 C2C12 
 The C2C12 cell line is an immortal line of mouse skeletal myoblasts derived 
from the thigh muscle of a C3H mouse after a crush injury. C2C12 cells grow as 
adherent monolayer and exhibit characteristic features of satellite cells. They are 
used to study the process of satellite cells activation, proliferation and differentiation. 
Because they are able to differentiate in contractile myotubes producing 
characteristic muscle protein, C2C12 are also used to study several aspects of 
skeletal muscle function and adaptation. They were purchased from ATCC (American 
Type Culture Collection, CRL-1772).  
3.2 Methods 
3.2.1 Preparation of cell culture media and buffers 
Table 4: Yeast culture medium components 
Stock solutions Components/concentration 
Minimal 
medium 
13.61 g KH2PO4, 1.98 g (NH4)2S04, 4.2 g KOH pellets, 0.2 g MgSO4, 1 
ml Fe2(S04)3 solution (40 mg/50 ml H20), 50 mg L-Ieucine, 50 mg L-
histidine, 50 mg adenine, 20 mg L-arginine-HCI, 20 mg L-methionine, 
30 mg L-tyrosine, 30 mg L-isoleucine, 30 mg L-lysine-HCI, 25 mg L-
phenylalanine, 100 mg L-glutamic acid, 150 mg L-valine, and 375 mg L-
serine 
to 1 L double-distilled water pH 7.1. 
Vitamin 
Solution 
8 mg thiamine, 8 mg pyridoxine, 8 mg pantothenic acid, 40 mg inositol, 
and 20 mL biotin solution (2 mg/100 mL H20) to 180 mL doulble-distilled 
water. 
L-aspartic Acid 4 mg/mL 
D-( + )-glucose 20% w/v  
L-threonine 24 mg/mL  
Copper Sulfate 20 mM 
*CPRG 10 mg/mL  
* Chlorophenol red-β-D-galactopyranoside 
The minimal medium and all other stock solutions were sterile filtered through 
0.2 μm filter and stored at 4°C in glass bottles. Growth medium was prepared by 
mixing 5 mL of glucose solution, 1.25 mL of L-aspartic acid solution, 0.5 mL of 
vitamin solution, 0.4 mL of L-threonine solution, 125μL of copper sulfate solution to 
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45 mL minimal medium solution. Assay medium was prepared by adding 0.5 mL of 
CPRG solution to fresh growth medium. 
Table 5: C2C12, HT-29 and MCF-7 cells growth media 
Cell line Medium composition    
C2C12 (Proliferation medium) 
420 mL DMEM   
50 mL FBS   
10 mL glutamin (4nM)  
5 mL penicillin/streptomycin (100U/L) 
5 mL sodium pyruvate (100mM) 
10 mL sodium bicarbonate (7.5%) 
HT-29 
450 mL DMEM   
50 mL FBS   
5 mL L-glutamin (4nM)  
10 mL penicillin/streptomycin (100U/l) 
MCF-7 (Normal growth medium) 
450 mL RPMI   
50 mL FBS   
5 mL L-glutamin (4nM)  
10 mL penicillin/streptomycin (100U/l) 
1.25 mL human Insulin (4mg/ml) 
 
 Charcoal-stripped FBS 
In experiments with the aim to assess the impact of E2 or PEs on cell 
proliferation, the steroids contained in FBS have to be removed in other to avoid any 
interference. To achieve this, activated charcoal was added to FBS (10 mg/mL) and 
the mixture shook for 1h at RT. The mixture was afterwards placed at 4 °C overnight 
to allow the charcoal to sediment. Then it was centrifuged (3500 rpm, 4 °C) and 
sterile filtered through a 0.2 μm syringe filter. 
 Buffers and solutions 
 Phosphate-buffered saline (PBS 0.1 M) 
 
                                                                                                           
                       
                                                                                                     Adjust the pH to 7.4 
 
 
Na2HPO4 *2H2O 14.4 g 
NaH2PO4* H2O 2.6 g 
NaCl 8766 g 
ddH2O 1L 
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 Tris-buffered saline (TBS 0.05 M) 
                   Tris                                                                        6.057 g 
                   NaCl                                                                      8.76 g  
                  ddH2O                                                                    1L 
                                                                      Ajust the pH to 7.6 with 1M HCl 
Depending on the purpose of use (antibody dilution, washing steps), both 
buffers were sometimes supplemented with 0.1% Tween 20. 
 TAE (Tris-Acetate-EDTA) buffer 
TAE buffer was used in agarose gel electrophoresis for the separation of RNA 
and DNA. 
For 1 L 50X TAE Stock Solution: 
                 Tris Base (MW=121.1 g/mol)                       242 g 
                 Glacial Acetic Acid                                       57.1 mL 
                 0.5 M EDTA (pH 8.0)                                    100 mL 
                 ddH2O                                                           1 L 
To prepare 1L of 0.5 M EDTA (pH 8.0) solution:  
                 EDTA (MW = 372.24 g/mol)                         186.1 g  
                 ddH2O                                                          1 L 
                Adjust the pH with 10 N NaOH (40 g NaOH in 100 mL ddH2O).  
 Lysis puffer 
This buffer was used for the preparation of proteins from cells. For 100 mL: 
Tris (50 mM) 0.605 g 
0.25% sodium deoxycholate 0.25g 
NaCl (150 mM) 0.8766g 
1 mM EDTA 0.0292g 
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1% Triton X 100 1mL 
                                                                                 Adjust the pH to 7.4 with HCl 
 
 Diethylpyrocarbonate (DEPC)-treated water. 
DEPC-treated water is suitable for dissolving RNA after its extraction from 
cells or tissues. To prepare 1L, 1 mL of DEPC was added in 999 mL ddH2O and 
placed overnight in a water bath at 37°C. Afterwards the water was autoclaved for 20 
min to remove the DEPC. 
 6X Sucrose loading buffer  
For 10 mL solution: 
         Sucrose                                           (40 % w/v)  
         Bromophenol blue                         0.25 %  
         Xylene xyanol                                 0.25 % 
 DNA Ladder 
The DNA ladder is a solution of DNA molecules of different lengths that is 
used in agarose gel electrophoresis as a reference to estimate the size of an 
unknown double-stranded DNA molecule. The DNA ladder was also used in total 
RNA quality control to estimate the location of the 28 S and 18 S ribosomal RNA 
bands. 
 For 1 mL solution: 
         100 bp DNA ladder                            50 μL  
         6x sucrose loading buffer                 166 μL  
         1x TAE buffer                                      784 μL 
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3.2.2 Plant material extraction 
The stem bark of E. excelsa was collected in Kumba (in the SouthWest region 
of Cameroon) in April 2011. The botanical sample was identified and authenticated at 
the Cameroon National Herbarium in Yaounde where a voucher specimen (N° 61487 
HNC) is deposited. The samples were air-dried (19-29°C), ground and 1.5 kg of the 
powder extracted at room temperature (22 ± 5°C) with ethanol (3× 6 l; 72 h each). 
After filtration, the solvent was removed using a rotary evaporator under reduced 
pressure. 
3.2.3 LC-HRMS and LC-HRMS/MS analysis 
An Accela Ultra High-Performance Liquid Chromatography (UHPLC) system 
hyphenated to a hybrid LTQ-Orbitrap Discovery Mass Spectrometer was employed 
for the extract profiling. The UHPLC system was equipped with an Accela pump, an 
Accela autosampler and an Accela PDA detector. Stock solution of 1 mg/mL (MeOH: 
H2O, 50/50, v/v) of the crude extract was prepared and 10 μL injected on a Hypersil 
Gold column (100 x 2.1 mm i.d., 3 μm particle size). The mobile phase used was 
aqueous acetic acid 0.1% (v/v) (solvent A) and acetonitrile (solvent B). The initial 
conditions were 98% of solvent A and 2% of solvent B adjusting linearly to 98% B in 
28 min. This solvent composition was maintained for 0.9 min (98% B) followed by a 
return to the initial conditions (in 0.1 min) and a re-equilibration step (1 min) prior to 
the next run. The flow rate was set to 500 μL/min and the wavelengths used for 
monitoring the chromatograms were 220, 280, and 365 nm (recording window 200 - 
700 nm).  
The mass spectrometer was equipped with electrospray ionization (ESI) 
source and operated in positive mode. A data dependent triple play method involving 
three scan events was developed for the profiling of the extract. This method 
consisted of a full scan acquisition, a Selective Ion Mode (SIM) and a MS/MS 
acquisition employing the Orbitrap analyzer and was designed so that the major ion 
detected in each full scan could be selected, scanned in SIM mode and fragmented, 
resulting to highly accurate MS and MS/MS spectra. For all measurements, the mass 
tolerance was set at 5 ppm. The ESI source was operated at a sheath gas flow rate 
of 50 arb, auxiliary gas flow rate of 10 arb, ion spray voltage of 3.5 kV, capillary 
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temperature of 300 oC, capillary voltage of 35 V, tube lens of 110 V and collision-
induced dissociation (CID) of 35% (HRMS/MS acquisitions). Xcalibur 2.0.7 software 
was used for the pre-and post acquisition of the results. 
3.2.4 Vacuum liquid chromatography (VLC) 
The column (200x15mm) was packed with 25 g of silica gel. The dry loading 
method was applied for sample application. 1g of the crude extract was dissolved in 
methanol, the resulting solution adsorbed on 3g of silica and the solvent allowed to 
evaporate. The dry adsorbent loaded with the sample was then applied to the column 
and eluted using a step gradient of solvent under vacuum. 250 mL fractions were 
collected at each polarity step and the column was allowed to run dry after each 
fraction collection. The solvent was evaporated to yield five fractions (Table 6) that 
were monitored for biological activity. 
Table 6:  VLC fractions. 
Fraction Solvent Weight (mg) 
F1 Cyclohexane(100%) 6.7 
F2 Cyclohexane - DCM(*) (50:50) 21.9 
F3 DCM(100%) 9.8 
F4 DCM - MeOH (50:50) 485 
F5 MeOH (100%) 24.1 
(*) Dichloromethane 
 
3.2.5 HPLC 
The HPLC system consisted of a vacuum degasser, a quaternary pump, an 
autosampler and a Diode-Array Detector (DAD). A Discovery SUPELCO HS C-18 
column (25 × 4.6 mm, 5 μm particle size) was used for separations. A binary mobile 
phase consisting of 1% acetic acid (A) and methanol (B) was used. The initial 
conditions were 50% A and 50% B. Then a gradient program was applied as follows: 
50-98% B and 50-2% A over 60 min, isocratic 98% B and 2% A for 5 min, return to 
the initial conditions over 5 min and maintain of these conditions for 10 min prior to 
the following injection. The injection volume was set to 20 μL and the flow rate to 
1mL/min. DAD conditions: 254, 280, and 365 nm and recording window from 200 to 
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700 nm. The control of the system as well as data acquisition and analysis were 
performed using ChromQuestTM 4.1 software. 
3.2.6 Yeast estrogen screen 
3.2.6.1 Principle 
The yeast estrogen screen (YES) (Figure 12) is a transactivation assay used 
to identify compounds that can interact with the human estrogen receptor (here hER-
α). In this system, yeast cells (saccharomyces cerevisiae) are transfected with hERα 
gene, together with expression plasmids containing estrogen-responsive elements 
and the lac-Z reporter gene encoding the enzyme β-galactosidase. Upon binding an 
active ligand, the receptor interacts with transcription factors and other transcriptional 
components to modulate gene transcription. This causes expression of the reporter 
gene lac-Z and the enzyme produced is secreted into the medium where it 
metabolizes a chromogenic substrate, chlorophenolred-β-D-galactopyranoside 
(CPRG) which is normally yellow, into a red product that can be measured by 
absorbance at 540nm. 
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Figure 12: Estrogen-inducible expression in yeast (Routledge and Sumpter, 1996). 
 
3.2.6.2 Assay procedure 
Yeast cells were stored at -80°C as 10X concentrated stock in growth medium 
supplemented with 15% glycerin. At day zero, growth medium was inoculated with 
yeast stock and incubated at 28°C till an OD of 1 at 690nm was attained 
(approximately 24h). The following day, chemicals serially diluted in DMSO were 
transferred (2μL) to 96-well optically flat bottom plates. Each plate contained one row 
(12 wells) of blanks (2μL DMSO only) and each assay had a 17β-estradiol standard 
curve (10-12-10-8 M). Assay medium was inoculated with the optimal yeast density of 
the 24 h culture prepared at day 0 and 200μL was given in each well. The plates 
were then sealed with autoclave tape and incubated at 32°C in a naturally ventilated 
heating cabinet on an orbital shaker. After 3 days of incubation, color change of the 
medium was quantified by absorbance at 540 nm. Yeast growth (turbidity) was 
measured at 620 nm.  
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3.2.6.3 Calculations 
Dose–response curves for β-galactosidase activity were obtained using 
corrected absorbance units (CAU):  
CAU = (AU 540nm) compound − [(AU 620nm) compound − (AU 620nm) 
blank]. The best-fitting curve was calculated with SigmaPlot for Windows, version 11 
using a four-parameter logistic regression according to the following formula: 
 
Hillslope x) (logEC50101
min -max
 min 


CAU  
 
min = baseline absorbance 
max = maximal absorbance 
EC50 = concentration of test compound yielding a half-maximal effect 
X= given concentration of test compound. 
Other parameters such as the relative induction efficiency (RIE) and the 
relative potency (RP) of each chemical were calculated as follows:  
 
100 
E2  min)-(max
compound  min)-(max
 RIE  
 
100 
Compound  (EC50)
E2  (EC50)
RP  
 
 
 
 
Material and methods 
M.Sc. Sadrine Tchoukouegno Ngueu  54 
 
3.2.7 MTT/XTT assays 
3.2.7.1 Principle 
Both assays are based on the cleavage of yellow tetrazolium salts MTT (3-
(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide) or XTT (2,3-Bis-(2-
Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) by mitochondrial 
succinate dehydrogenases of metabolic active cells. The colored (dark purple for 
MTT and orange for XTT) formazan product is then measured spectrophotometrically 
and correlates to cell viability since the reduction of tetrazolium salts can occur only 
in metabolically active cells. The difference between the two assays is that the XTT is 
performed in the presence of an electron- coupling reagent and the formazan product 
formed is water-soluble and does not require a further solubilization step as it is the 
case for MTT. 
3.2.7.2 Assay procedure 
Breast cancer (MCF-7) and colon carcinoma (HT-29) cell lines were used. The 
cell culture media were prepared as indicated in Table 5. For the assay, the cells 
were washed with phosphate buffered saline (PBS) and detached with 0.05 % 
trypsin-EDTA. After centrifugation, the pellet was resuspended in medium, the cells 
counted and diluted to give the optimal seeding density (104 cells/well). The cells 
were further plated into a 96-well plate, allowed to attach for 24-48 h and incubated 
for 3 or 5 days with either cisplatin or the plant extract dissolved in DMSO. Each 
concentration was added to the plates in six replicates. The final DMSO 
concentration was not more than 0.1%, this concentration being used in the solvent 
control wells. 
3.2.8 Myotubes diameter assay 
C2C12 cells were routinely cultured in a proliferation medium (Table 5). They 
were passaged 2 to 3 times/week (at 80% confluence) to avoid confluence that would 
cause a depletion of the myoblast population. For the assay, myoblasts in PM were 
seeded at a density of 105 cells/well in 6-well plates. Differentiation towards 
myotubes was induced on the 3rd day (at confluence) by shifting the proliferation 
medium (PM= DMEM+10% foetal bovine serum) to a differentiation medium (DM= 
Material and methods 
M.Sc. Sadrine Tchoukouegno Ngueu  55 
 
DMEM supplemented with 2-10% horse serum). Myotubes at day 4-6 post-fusion 
were incubated for 48 h with the different substances (Table 7). At the end of the 
treatment period, cultures were fixed in 2.5% glutardialdehyde and photographed by 
glutaraldehyde-induced autofluorescence using an Axiovert 200 M microscope 
equipped with a HaL 100 camera. Average diameters of at least 50 myotubes were 
measured for each condition at different points separated by 25-50 µm along the 
length of the myotube (Stitt et al., 2004) using the Axiovision LE software. 
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Table 7: Experimental groups myotube diameter assay. 
 
3.2.9 Western blot 
3.2.9.1 Protein preparation from C2C12 cells 
C2C12 cells were cultured and seeded for this assay as previously mentioned 
with the difference that they were allowed to grow to confluence and to differentiate in 
normal growth medium. At 10 days old, cells were incubated for 72h in the presence 
of either E2 (10-8 M) or vehicle control (DMSO) and the lysate prepared. 
Cell culture dishes were placed on ice and the cells washed twice with ice-cold 
PBS. Then ice-cold lysis buffer supplemented with protease enzyme inhibitor PMSF 
(phenylmethanesulfonylfluoride, dissolved in isopropanol) at final concentration of 1 
mM was added directly in the dishes and the cells scraped off using a cold plastic 
scraper. The cell suspension was transferred into pre-cooled micro centrifuge tubes 
and maintained for 30 min on ice. After 20 min centrifugation at 12000 rpm, the 
supernatants were transferred in new tubes and the protein concentration 
determined.  
3.2.9.2 Determination of protein concentration 
The total level of protein in each sample was determined using the BIO-RAD 
DC Protein Assay which is based on the Lowry method (Lowry et al., 1951). BSA 
(Bovine Serum Albumin) standard protein samples ranging from 0 to 2 mg/mL were 
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prepared in lysis buffer and the myotubes protein samples diluted up to 1: 5. Then 5 
µL of each sample protein was introduced in each well of a microplate reader 
followed by 25 µL Reagent A and 200 µL Reagent B. After 15 min of incubation at 
room temperature (RT), the absorption at 650 nm was read using a microplate 
reader. The protein samples were stored at -80°C till further use. 
3.2.9.3 SDS gel electrophoresis 
Sample protein (20 μg) were mixed with equal amounts of SDS-loading buffer 
and loaded on a NuPAGE Novex 4–12% Bis–Tris Midi Gel. After migration at 90 mA 
for 60 min using the XCell4 SureLock™ Midi-Cell electrophoresis system, proteins 
were blotted for 30 min at 25V, 1A (Trans-Blot®Turbo™ Transfert System) onto 
nitrocellulose membranes (Protran®Nitrocellulose Membranes). The membranes 
were blocked for 1h at room temperature with 5% dry milk powder in Tris-buffered 
saline with 0.1% Tween 20 (TBS-T). The membranes were incubated overnight at 
4°C with either β-actin or ERβ antibody diluted (Table 2) in 1% dry milk powder in 
TBS-T. After four times wash with TBS-T for 10 min each, the membranes were 
incubated for 1h at RT with the corresponding secondary antibody solution. After 
another four times wash (10 min each) in TBS-T, blot signals were visualized by the 
chemoluminescent POD-Substrate and the images analyzed using the Image J 1.40g 
software. 
3.2.10 Uterotrophic assay 
Juvenile female Wistar rats aged 6 weeks were ovariectomized. After 14 days 
of endogenous estrogens decline, the animals weighing 200-250g were randomly 
distributed into treatment and vehicle groups (Table 8) and treated for three 
consecutive days with a daily dose. The animals were sacrificed by decapitation 24 h 
after the last dose. Uterine and liver wet weights were recorded. Half of the uteri were 
kept together with vaginas in 4% formaldehyde for subsequent histological analysis 
and the rest of the uteri as well as the livers were snap frozen in liquid nitrogen for 
RNA preparation. 
 
 
Material and methods 
M.Sc. Sadrine Tchoukouegno Ngueu  58 
 
Table 8: Groups treatment uterotrophic assay 
Groups Dose Number of animal 
Control 
1 mL/kg BW career (20% DMSO + 80% 
corn oil) 
7 
E2 4 μg/kg BW 7 
E.excelsa 
50 mg/kg BW 6 
100 mg/kg BW 6 
 
3.2.11 Histological analysis of tissues 
The standard paraffin process that includes fixation, processing, embedding, 
sectioning, and staining was used for historical anlaysis of tissues. 
3.2.11.1 Fixation 
To prevent the degenerative process that takes place when tissues are 
deprived from their blood supply, tissues were put in cassettes carrying details for 
their identification and kept in a 4% formalin solution right after their preparation. 
 
3.2.11.2 Dehydration and clearing 
To allow cutting, tissues have to be infiltrated with paraffin wax that is however 
not soluble in water or alcohol but in a solvent called xylene or xylol which is miscible 
with both alcohol and paraffin. The water that is contained in tissues was removed by 
passing the tissues through increasing concentrations of ethanol (50-100%). Finally, 
the alcohol that replaced the water was replaced by xylol. The specimens were 
afterwards transferred in molten wax (60°C) in an embedding centre. 
 
3.2.11.3 Embedding 
The specimens were removed from their cassettes and placed in wax filled 
molds according to the desired orientation (transversal and/or longitudinal). The 
cassettes were then placed on top of the molds and the now called “block” allowed to 
solidify on a cold surface.  
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3.2.11.4 Sectioning 
Sections of 5-7 μm were cut on a microtome (Mod. 1140/Autocut), flatted on 
the surface of warm water and picked up onto polysine microscope slides. 
 
3.3.11.5 Staining 
Hematoxylin-eosin (HE) was used as the staining technique. Because staining 
solutions used are aqueous, the wax had to be removed and the sections rehydrated. 
The sections were first incubated at 60°C for 1h (Hereaus B5042 incubator) and were 
afterwards passed in xylene and decreasing concentrations of ethanol as follows: 
 
Xylol 1 15 min 
Xylol 2 10 min 
Xylol 3 10 min 
100% EtOH 1 5 min 
100% EtOH 2 5 min 
96% EtOH 1 5 min 
96% EtOH 2 5 min 
70% EtOH 1 5 min 
70% EtOH 2 5 min 
Distilled water 5 min 
The slides were immersed in different solutions as follows: 
1. Mayer‟s hemalun  5 min 
2. Tape water   5 min 
3. Eosin     2 min 
4. Distilled water    Briefly 
5. EtOH 70 %    2-3 min 
6. EtOH 96 %    2-3 min 
7. EtOH l 100 %    2-3 min 
8. Xylol      2-3 min 
9. Mounting with coverslips and mounting medium. 
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3.2.12 Gene expression analysis 
3.2.12.1 RNA preparation from cells and tissues 
 The total cytoplasmic RNA was extracted from cells and tissues using the 
standard TRIzol® method according to the manufacturer‟s instructions (Invitrogen, 
Life Technologies). For the animal experiment, tissue samples from the same 
treatment group were pooled. 
 
 3.2.12.2 RNA concentration and quality control 
 RNA concentration was obtained by measuring the absorbance at 260nm 
using a NanoDropTM 1000 spectrophotometer. The purity of the extracted RNA was 
estimated by the ratio between absorbance at 260 and 280nm and its integrity 
controlled by agarose gel electrophoresis and ethidium bromide staining. 
 
3.2.12.3 Complementray DNA (cDNA) synthesis 
 Synthesis of cDNA including the removal of genomic DNA was performed 
using the QuantiTect® Reverse Transcription Kit of Qiagen according to the provided 
instructions. The incubation steps were performed in a GeneAmp PCR system 9600 
thermocycler. 
 
3.2.12.4 Primer design 
 The genomics sequences available at the University of California Santa Cruz 
Genome Bioinformatics site (UCSC genome browser) and the Primer3 software 
(Whitehead Institute for Biomedical Research, Cambrigde, USA) were used to design 
primers (sequences in Table 9). The specificity of the designed primer was checked 
using the BLAST program of the NCBI (National Centre for Biotechnology 
Information). The design criteria were as follows: 
 Melting temperature: between 58°C and 60°C 
 Length: 18-23 bp 
 Amplicon length: 150-200 bp 
 G/C content: 40-60% 
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Table 9: Primer Sequences 
Gene name Forward and reverse primers Amplicon size (bp) 
Mouse  
Cyclophilin (CYC) 
GGATTCATGTGCCAGGGTGG 
212 CACATGCTTGCCATCCAGCC 
   
ERα 
TGTTTGCTCCTAACTTGCTCCT 
222 GGTGGATGTGGTCCTTCTCTT 
Rat 
1A 
CGTCACAGCCCATGCATTCG 
212 CTGTTCATCCTGTTCCAGCTC 
   
C3  
CAGCCCGCAGAGTGCCAGTAGTC 
 CCATCCTCCTTTCCATCAACTGC 
   
Clusterin 
CCCTTCTACTTCTGGATGAA 
 GAACAGTCCACAGACAAGAT 
   
IGFBP-1  
GATTAGCTGCCGCTCAACAG 
283 TTCCCACTCCATGGGTAGAC 
   
CaBP9k  
ATCCAAACCAGCTGTCCAAG 
181 TGTCGGAGCTCCTTCTTCTG 
Human 
1A 
CTATAGTGGAGGCCGGAGCAGCAA 
203 GAGGGGCGTTTGGTATTGGGTTATG 
   
BAX 
AACATGGAGCTGCAGAGGA 
 GGAGGAAGTCCAATGTCCAG 
   
BCL-2 
GGATGCCTTTGTGGAACTGT 
 GCCTGCAGCTTTGTTTCAT 
   
CCND1 
TCGGTGTCCTACTTCAAATGTGT 
233 GGGATGGTCTCCTTCATCTTAG 
 
3.2.12.5 Quantitative realtime RT-PCR 
 Real-time RT-PCR was performed in a MX3005P thermal cycler. The protocol 
consisted of a denaturing cycle at 94-95 °C for 4 min followed by 40 cycles of 20 s at 
Material and methods 
M.Sc. Sadrine Tchoukouegno Ngueu  62 
 
94-95 °C, 20-30 s at 58-60 °C, and 30 s at 72°C. The reaction setup and the cycling 
conditions are resumed in Tables 10 and 11. 
Table 10: PCR reaction mix. 
Components 25 μL reaction 50 μL reaction Final [] 
Ampuwa 16.425 32.85 _ 
10X PCR buffer 2.5 5 1X 
MgCl2 (50 mM) 1.5 3 3 mM 
dNTPs (2.5 mM) 1 2 0.1 mM 
Primer mix (10 mM each ) 0.5 1 0.2 mM 
Template DNA  0.5 1 _ 
Taq-polymerase (5U/μL) 0.075 0.15 0.75 U 
Sybr green (1X) 2.5 5 0.1X 
 
Table 11:  PCR cycling conditions. 
Cycle Step  Temperature Time Description 
1 Segment 1 94-95°C 4 min Initial denaturation  
40-45 Segment 2 
94-95°C 20s 
Template denaturation, Primer 
annealing and Extension 58-60°C 20-30s 
72 °C 30s 
1 Segment 3 
95°C 1 min Flourescnece data collection, 
dissociation (melting) curve 
analysis  
55°C 30s 
95°C 30s 
 
3.2.12.6 Analysis of real time RT-PCR results 
Expression levels of the analyzed genes were normalized to the housekeeping 
gene (cytochrome C oxidase or 1A) and correlated to the untreated control animal 
group using the ΔΔCt method (Pfaffl, 2001). This method assumes that the DNA 
amplification efficiency is 100% or equal to 1 and proposes the following formula for 
the calculation of the amount of target gene: 
Expression level target gene (Fold induction) FI = 2 -∆∆Ct where: 
Ct = cycle number at which the fluorescence crosses the threshold (threshold cycle) 
ΔCt = Ct target-Ct reference 
ΔΔCt = ΔCt target- ΔCt control 
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3.2.13 Cell cycle analysis 
The analysis of cell cycle is based on the ability to stain cellular DNA in a 
stoichiometric manner, i.e. the amount of stain is directly proportional to the amount 
of DNA within the cell. Because the DNA amount changes between the different 
phases during the cell cycle, the measure of DNA content in cells by flow cytometry is 
a powerful tool that allows the study of how chemicals affect cell cycle distribution 
and progression. For the assay, MCF-7 cells were routinely cultured in the normal 
growth medium as indicated in Table 5. To avoid any influence of steroids contained 
in the serum, FBS was stripped with 0.5% charcoal and the medium containing 
charcoal-treated FBS (assay medium) used for the assay. The cells were plated at a 
density of 2x105 cells/well in 6 -well plates and pre-incubated 48 h in assay medium 
prior to the treatment. The procedure is represented in Figure 13. All the test 
chemicals (see Table 12 for different groups) were dissolved in DMSO and the final 
DMSO concentration in each well was not more than 0.1%. The cell cycle distribution 
was analyzed using a BD FACSCalibur flow cytometer. 
Table 12: Experimental groups for the cell cycle analysis. 
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Figure13: Cell culture procedure for cell cycle analysis. 
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3.2.14 Immunocytochemistry 
This method was applied for the detection of apoptosis of MCF-7 cells using 
the M30 CytoDEATH antibody that recognizes a specific caspase cleavage site 
within cytokeratin 18 (Roche, Mannheim Germany). MCF-7 cells were plated in 24-
well plates (5x104 cells/well), pre-incubated for 48 h with charcoal treated-FBS 
medium and exposed for 6h to the test chemicals. The following protocol provided by 
Roche was used with some modifications: 
1.  Washing of cells with PBS 
2. 30 min fixation  at -20°C in ice-cold pure methanol 
3. 
2 x 5 min wash with washing buffer (PBS+0.1% 
Tween 20) 
4. 
Incubation with 100 µL/well M30 CytoDEATH antibody 
(diluted 1/10 in washing buffer containing 1% BSA) at 
4°C overnight 
5. 2 x 5 min wash with washing buffer  
6. 
Incubation with polyclonal goat anti-mouse Ig, 
biotynylated (diluted 1/200 in PBS) for 1h at RT 
7. 2 x 5 min wash with washing buffer  
8. 
Incubation with streptavidin-cy3 (diluted 1/1000 in 
PBS) for 1h at RT 
9. 2 x 5 min wash with washing buffer  
10. Incubation with Dapi (1/1000 in PBS) for 3 min at RT 
11. 2 x 5 min wash with washing buffer  
12. Acquisition of photos using fluorescence microscope  
 
Photos were taken and analyzed with an Axiovert 200 M inverted fluorescence 
microscope equipped with an HL 100 camera. At least 1000 cells/treatment groups 
were counted and the apoptotic index calculated according to the following formula:  
100
cellsof  number  Total
cells positive  M30of  Number
 index  Apoptotic  
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3.2.15 Statistical analysis 
All data are expressed as mean±SD and were statistically analyzed with SPSS 
17.0-21.0 for Windows. Kruskal-Wallis H-test and the Mann–Whitney U-test were 
used and significance level set at P < 0.05. 
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4.1 Biological activities and chemical characterization of Erythrina 
excelsa 
 
4.1.1 Estrogenic and Cytotoxic properties of E.excela whole extract 1 
4.1.1.1 Yeast estrogen screen 
The ability of E. excelsa whole ethanol extract to interact with the human 
estrogen receptor alpha was assessed using the yeast transactivation assay. As 
shown in Figure 14A, E. excelsa similarly to E2 and genistein dose-dependently 
induced lac-Z reporter gene expression. Yeast growth was inhibited by 
concentrations of extract above 10 μg/mL (data not shown). The EC50 values as well 
as RIEs and RPs are summarized in Table 13. The response of the yeast to E. 
excelsa was antagonized by the pure anti-estrogen ZK (Figure 14B). In the anti-
estrogenic activity assay, only ZK was able to produce a full dose-response effect 
(Figure 14C). 
                                                          
1
 These results are submitted as original research article in planta medica 
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Figure 14: Effect of E. excelsa whole extract as compared to genistein and E2 on the 
expression of β-galactosidase in yeast cells. The graph depicts the concentration of 17β-
estradiol, genistein, ZK and E. excelsa ethanolic extract plotted against the CAUs of the 
medium after 3 days of incubation (A) estrogenicity; (B) antagonism of E. excelsa with ZK 
and (C) anti-estrogenicity. 
 
Table 13: Yeast assay results with E. excelsa whole extract. 
  EC50 (μg/mL) EC50 (M) RIE (100%) RP 
E2 2.34x10-5 ± 1.76x10-6 8.6x10
-11 ± 6.5x10-12 100 100 
Genistein 0.2 ± 0.0282 7.4x10-7 ± 1.07x10-7 90.2 1.6x10-2 
E. excelsa 1.8 ± 0.2   67.45 1.3x10-3 
 
Results 
M.Sc. Sadrine Tchoukouegno Ngueu  70 
 
 
4.1.1.2 Uterotrophic assay 
4.1.1.2.1 Effect of E. excelsa whole extract on the uterus 
 Uterine wet weight and epithelial height 
 E. excelsa at a dose of 50 mg/kg BW/day like E2 led to a significant increase 
of uterine wet weight and uterine epithelial height but was less potent. At 100 mg/kg 
BW/day, a significant decrease of uterine wet weight and a tendency to a decrease of 
the uterine epithelial height were observed (Figure 15). 
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Figure 15: (A) Uterine wet weight (mg/kg BW) and (B) uterine epithelial height (µm) after 3-
day subcutaneous treatment of ovariectomized Wistar rats with either E. excelsa ethanolic 
extract (50 and 100 mg/kg BW/day) or E2 (4 µg/kg/BW/day). (C) 100X Microphotographs of 
uterine tissue following a Hematoxylin-Eosin (HE) staining. Mean values ± S.D. are given for 
n = 6 animals per dose group ** p≤ 0.01;*p≤0.05, significantly different from the control group 
(Ovex), Kruskal-Wallis H-test followed by Mann–Whitney U-test. 
 
 Uterine C3 and clusterin mRNA expression 
 As expected, Clusterin mRNA expression was down-regulated and C3 up-
regulated following treatment with E2. In response to the treatment with 50 mg/kg 
BW/day of E. excelsa ethanolic extract, the same but less pronounced gene 
expression pattern was detected. The 100 mg/kg dose of E. excelsa, unlike the 50 
mg dose, caused a significant up-regulation of Clusterin and a down-regulation of 
C3 (Figure 16). 
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Figure 16: (A) Relative mRNA expression of C3 and (B) clusterin (normalized to the 
mRNA amount of 1A and compared to the vehicle control group) in the uterus of 
ovariectomized Wistar rats treated subcutaneously for 3 consecutive days with 50 and 
100 mg/kg BW/day E. excelsa ethanolic extract and 4 µg/kg/BW/day E2. * P≤0.05 
significantly different from the control group (Ovex), Kruskal-Wallis H-test followed by 
Mann-Withney U-test. 
 
4.1.1.2.2 Effect of E. excelsa whole extract on the vagina 
E2 increased the vaginal epithelial height by approximately 5-fold. No 
significant effects of E. excelsa could be detected at both doses, but clear tendencies 
of either increase or decrease were seen (Figure 17).  
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Figure 17: (A) Vaginal epithelial height (µm) after 3-day subcutaneous treatment of 
ovariectomized Wistar rats with either E. excelsa ethanolic extract (50 and 100 mg/kg 
BW/day) or E2 (4 µg/kg/BW/day). (B) 100X Microphotographs of vagina tissue following a 
Hematoxylin-Eosin (HE) staining. Mean values ± S.D. are given for n = 6 animals per dose 
group ** p≤ 0.01;*p≤0.05, significantly different from the control group (Ovex), Kruskal-Wallis 
H-test followed by Mann–Whitney U-test. 
 
4.1.1.2.3 Effect of E. excelsa whole extract on the liver IGFBP-1 and CaBP9k 
mRNA expression 
The 50 mg/kg dose of E. excelsa similar to E2 significantly increased the 
mRNA expression of IGFBP-1 and CaBP9k, whereas the 100 mg/kg dose led to a 
significant down regulation of the two genes (Figure 18). 
Results 
M.Sc. Sadrine Tchoukouegno Ngueu  74 
 
 
Figure 18: Relative mRNA expression of (A) IGFBP-1 and (B) CaBP9k (normalized to the 
mRNA amount of 1A and compared to the vehicle control group) in the liver of 
ovariectomized Wistar rats after 3-day subcutaneous administration of 50 and 100 mg/kg 
BW/day E. excelsa ethanolic extract and 4 µg/kg/BW/day E2. *P≤0.05, Kruskal-Wallis H-test 
followed by Mann-Withney U-test. 
 
4.1.1.3 MTT assay 
The effect of E. excelsa whole extract on the growth of breast (MCF-7) and 
colon (HT-29) cancer cell lines was investigated using the MTT cytotoxicity/cell 
viability assay. A slight and non significant increase of the viability of MCF-7 cells was 
caused by lower concentrations of E. excelsa. At higher concentrations however, cell 
death was observed. The extract was cytotoxic on HT-29 cells at all tested 
concentrations and was less potent than the chemotherapeutic drug cisplatin (Figure 
19).  
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Figure 19: Effects of E. excelsa whole extract on the growth of (A) MCF-7 and (B) HT-29 
cells. Results present the average and standard deviation of n≥3 independent experiments 
performed in 6 replicates for each concentration. 
 
4.1.2 Effect of a phytoestrogenic fraction of E. excelsa on the growth of the 
human breast cancer line MCF-7. 
Here, the above mentioned crude ethanol extract was fractionated by vacuum 
liquid chromatography and the fractions monitored for both estrogenic (YES) and 
cancer growth inhibitory (XTT) properties. 
4.1.2.1 Yeast estrogen screen 
From the 5 fractions obtained by VLC, F4 and F5 were able to induce the 
transactivation of the hERα as depicted on Figure 20. Based on the calculated EC50 
values (Table 14) F4 was almost as potent as the whole extract and 13.47 times 
more potent than F5. 
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Figure 20:  Effect of fractions of E. excelsa on the expression of β-galactosidase in yeast 
cells. (A) VLC fractions, (B) active fractions compared to the whole extract. The graphs 
depict the concentration of test chemicals plotted against the CAUs of the medium after 3 
days of incubation. 
 
Table 14: Yeast assay results with VLC fractions. 
Substance EC 50(μg/ml)  RIE (%) RP 
E2  5.08 x 10
-5 
± 4.64 x10
-6
 100   
F1  -   -  
F2  -   -  
F3  -   -  
F4  1.1 ± 0.0174  70.37 4.62 x 10
-3
 
F5  14.8 ± 6.7 35.06 3.43 x 10
-3
 
 
4.1.2.2 XTT 
To test whether the two estrogenic fractions also conserved the cytotoxic 
ability exhibited by the whole extract, their effect on MCF-7 cell growth was assessed 
using the XTT assay. To minimize the influence of the steroids presents in FBS, the 
assay was performed with a medium supplemented with charcoal stripped FBS. As 
shown in Figure 21, both fractions at lower concentrations induced a slight but not 
significant increase in cell viability. At higher concentrations, F4 induced a 
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concentration-dependent decrease of cell number but was less cytotoxic than the 
whole extract. 
 
Figure 21: (A) Effect of estrogenic fractions of E. excelsa ethanol extract on MCF-7 cell„s 
viability. (B) F4 compared to the whole extract.  MCF-7 cells were incubated for 72 h with 
increasing concentrations of fractions or whole extract and the cell viability examined by 
XTT.* (p≤0.05) and *** (p<0.001) vs. control analyzed by Kruskal Wallis H-test followed by 
Mann Whitney U-test. 
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4.1.2.3 HPLC fingerprints of F4 and E. excelsa whole extract 
 
 
Figure 22: HPLC chromatograms of E. excelsa whole extract and F4 fraction 
 
Based on the results obtained in YES and XTT, F4 was the most potent 
fraction with respect to both estrogenicity and cytotoxicity and was chosen for further 
analysis. 
4.1.2.4 Effect of F4 on MCF-7 cell cycle distribution 
As on cell viability, a biphasic effect of F4 on cell cycle distribution was 
observed. Similarly to E2, F4 at lower concentrations stimulated the G1/S transition 
leading to an increased percentage of cells in S and G2/M phases. At the same time, 
a concentration-dependent decrease of the percentage of subG1 population (death 
cells) was observed. With higher concentrations of F4, although not significant, a 
concentration-dependent increase of the percentage of cells in G0/G1 was observed 
followed by a decrease of the percentage of cells in S but not in G2/M phase. Higher 
concentrations of F4 also increased the percentage of the subG1 population (Figure 
23).
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Figure 23: Effects of F4 on the cycle distribution of MCF-7 cells. MCF-7 cells were incubated for 48 h with increasing concentrations of F4 and 
the cell cycle distribution assessed by flow cytometry. (A) Representative Histogramms and (B) mean of n≥ 3 independent experiments. a 
(p≤0.05), b (p<0.01), c (p<0.001) vs. control analyzed by Kruskal Wallis H-test followed by Mann Whitney U-test. 
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4.1.2.4.1 Antagonisation with ZK 
To elucidate the role of ER in the estrogen-like effects of lower concentrations 
of F4, an antagonization experiment with a pure antiestrogen (ZK) was performed. 
Treatment with ZK alone led to G1 arrest (indicated by a significant increase of the 
percentage of the cells in G1 with a concomitant significant decrease in the 
percentage of S and G2/M populations) and to an increase of cell death. ZK 
antagonized the effects of E2 as well as F4 on almost all phases of the cell cycle 
(Figure 24). 
 
Figure 24: Role of ER in F4-mediated effects on the cycle distribution of MCF-cells. MCF-7 
cells were cotreated for 48 h with F4 and the pure anti-estrogen ZK and the cell cycle 
analyzed by flow cytometry. * (p≤0.05), ** (p<0.01), *** (p<0.001) vs. Control; + (p≤0.05), ++ 
(p<0.01), +++ (p<0.001) vs. single treatment analyzed by Kruskal Wallis H-test followed by 
Mann Whitney U-test. 
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4.1.2.4.2 Cotreatment with E2 
To test for ER antagonism activity of F4, MCF-7 cells were simultaneously 
treated with increasing concentrations of F4 and 10-10 M E2 (Figure 25). Analysis of 
the cell cycle following cotreatment with lower concentrations of F4 and 0.1 nM E2 
shows some antagonistic patterns on both SubG1 and S phases. In fact single 
treatment with F4 at those concentrations or with E2 decreased the percentage of the 
subG1 cell population and cotreatment brought this percentage back to control levels. 
The same effect was observed on the percentage of S-phase cells with 1 μg/mL F4.  
In contrast to subG1 and S, additive effects were observed on Go/G1 and M phases. 
Cotreatment with E2 did not rescue the cells from death induced by higher 
concentrations of F4 rather, E2 addition led to even more pronounced cell death. On 
the other hand E2 addition induced more cells to transit from G1 to S phase.  
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Figure 25: Effect of the cotreatment with E2 and lower (A) and higher (B) concentrations of 
F4 on the cycle distribution of MCF-7 cells. MCF-7 cells were treated for 48h with various 
concentrations of F4 together with 0.1 nM E2 and the cell cycle distribution analyzed by flow 
cytometry. * (p≤0.05), ** (p<0.01), *** (p<0.001) vs. Control; + (p≤0.05), ++ (p<0.01), +++ 
(p<0.001) vs. single treatment analyzed by Kruskal Wallis H-test followed by Mann Whitney 
U-test. 
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4.1.2.5 M30 staining 
To assess the cell death process sustaining the increase of subG1 population 
induced by higher concentrations of F4, the caspase cleaved cytokeratin 18 that is a 
marker of early apoptosis was investigated. Figure 26 shows clear tendency of a 
concentration-dependent increase of the percentage of M30 positive cells following 
treatment with F4. 
 
 
Figure 26: Effect of F4 on caspase-cleaved cytokeratin 18 in MCF-7 cells. MCF-cells were 
exposed for 6h to either ZK (10-
6 
M) or increasing concentrations of F4 and the protein 
expression of caspase-cleaved cytokeratin 18 measured by indirect immunofluorescence 
using the M30 CytoDEATH antibody as described in material and methods. (A) 
Representative fluorescence microscopy images (100 X magnitude), (B) quantitative analysis 
of M30 positive cells. 
 
4.1.2.6 Effect of F4 on the mRNA expression of CCND1, Bax and Bcl-2 in MCF-7 
cells 
CCND1 mRNA was upregulated following treatment with E2 and 10 μg/mL F4, 
and downregulated by ZK and 50 μg/mL of F4. E2 and F4 at low concentration acted 
differently on Bax and Bcl-2 expression but both significantly downregulated the 
Bax/Bcl-2 ratio. E2 had no effect on Bax and upregulated Bcl-2 whereas F4 had no 
effect on Bcl-2 but downregulated Bax. At high concentration, F4 as well as ZK 
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induced a concomitant upregulation of Bax and downregulation of Bcl-2 leading to an 
increased Bax/Bcl-2 ratio (Figure 27). 
 
Figure 27: Effects of F4 on the mRNA expression of Bax (A), Bcl-2 (B), Bax/Bcl-2 ratio (C), 
and Cyclin D1 (D) in MCF-7 cells. MCF-7 cells were treated for 48h with the tests chemicals 
and the expression level of target genes assessed by real-time RT-PCR. ** (p<0.01) 
analyzed by Kruskal-Wallis H-test followed by Mann Whitney U-test. 
 
4.1.3 Chemical characterisation of E. excelsa ethanol extract2 
The LC-PDA-ESI (+)-HRMS analysis revealed the rich metabolic content of E. 
excelsa. The analytical effort was focused on the identification of the major 
compounds of the extract as well as the characterization of chemically representative 
secondary metabolites. The applied separation and spectroscopic method was 
developed aiming to cover the entire spectrum of polarities, thus giving an inclusive 
overview of the chemical nature of the extract (Figure 28, Table 15). UV-Vis spectra, 
suggested elemental composition (EC), Ring Double Bond equivalent (RDBeq) 
values as well as highly accurate mass measurements were incorporated for the 
identification procedure. Additionally, the HRMS/MS spectra found to be critical to the 
                                                          
2
 Included in the Research article submitted in Planta Medica 
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identification procedure supporting the structural information were obtained from the 
HRMS analysis in full scan (Figures 29-36). 
 
Figure 28: Base Peak chromatogram of Erythrina excelsa ethanol extract and Extracted Ion 
Chromatograms (XICs) of representative isoflavonoids detected.  
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Table 15: Representative Isoflavonoids of Erythrina excelsa ethanol extract using LC-PDA-ESI (+)-LTQ-Orbitrap platform. 
 
 
Rt 
(min) 
[M+H]
+
 Experimental 
m/z 
Theoritical 
m/z 
Δm(mmu/ppm)/ 
ppm) 
RDB λmax 
(nm) 
Main MS / MS fragment ions (Relative abundance, %) Chemicalclass 
(Identification) 
1 7.91 C15H11O4 255.0663 255.0652 1.125 / 4.409 10.5 261 255 (100), 237 (18), 227 (43), 211 (4), 199 (85), 137 (43) 
Simple isoflavone 
(Daidzein) 
2 9.53 C15H9O5 269.0435 269.0444 -0.900 / -3.345 11.5 262, 342 Not found  Coumestan (coumestrol) 
3 11.43 C20H19O6 355.1187 355.1176 1.095 / 3.084 11.5 267 337 (100), 319 (5), 309 (8), 295 (37), 283 (77), 271 (2) Prenyl isoflavonoid 
4 12.11 C25H27O7 439.1761 439.1751 0.960 / 2.255 12.5 234, 270 
421 (11), 403 (49), 385 (9), 368 (24), 349 (100), 295 (8), 
213 (6) 
Dipyran isoflavonoid 
5 14.83 C20H9O5 339.1234 339.1227 0.710 / 2.093 11.5 228, 267 283 (100) Prenyl isoflavonoid 
6 16.12 C25H25O6 421.1651 421.1646 0.535 / 1.270 13.5 232, 280 403 (100), 349 (10) Dipyran isoflavonoid 
7 16.69 C20H17O5 337.1076 337.1071 0.520 / 1.542 12.5 228, 282 
337 (8), 322 (19), 319 (69), 309 (15), 295 (31), 283 (100),  
267 (15) 
Pyran isoflavonoid 
8 17.22 C25H27O6 423.1803 423.1802 0.085 / 0.201 12.5 237, 271 405 (42), 367 (100), 351 (3), 349 (39), 295 (2) 
Pyran prenyl 
isoflavonoid 
9 18.56 C25H27O5 407.1851 407.1853  -0.180 / -0.443 12 .5 239, 271 351 (100), 295 (10) Diprenyl isoflavonoid 
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The great majority of the detected secondary metabolites were isoflavonoids. 
For instance compound 1 (Rt = 7.91 min) was identified as daidzein based on its 
accurately measured pseudomolecular ion [M+H]+ at m/z 255.0663 with an RDBeq. 
value of 10.5 (positive mode). HRMS/MS spectra verified its structure through the 
characteristic [M+H-CO]+, [M+H-CO-CO]+ and 1,3A+ ions (Figure 29) (Lee et al., 
2005).  
 
Figure 29: HRMS/MS spectrum of compound 1. 
 
Coumestans were also detected. For example, the well-known phytoestrogen 
coumestrol (compound 2, Rt = 9.23 min) was identified by its pseudomolecular ion at 
m/z 269.0435 and its characteristic UV spectra as well as the RDBeq. value of 12.5 
(positive mode) (Antignac et al., 2003). 
Except isoflavones and coumestans, several mono- and di-pyran and prenyl 
derivatives of isoflavonoids seem to dominate the extract and thus comprising its 
most characteristic chemical group. Some representative prenylated and pyran 
isoflavonoid derivatives are listed in Table 15. Similarly to the above mentioned 
compounds, they were identified from their accurately measured spectrometric data 
and additional spectrometric features while fragmentation patterns mostly related to 
specific mass losses at their HRMS/MS spectra supported drastically their 
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identification. In particular, the nominal mass losses of 56 Da (C4H8) characteristic of 
prenyl group and 54 Da (C4H6) for pyran ring were widely observed at the HRMS/MS 
spectra of compounds 3-9 (Simons et al., 2009). Specifically, at the HRMS/MS 
spectra of compounds 3 (Figure 30) (Rt = 11.43 min), 5 (Figure 31) (Rt = 14.83 min) 
and 9 (Figure 32) (Rt = 19.56 min), the typical loss of 56 Da (C4H8) is observed 
indicating the occurrence of at least one prenyl side chain at the basic skeleton of 
these isoflavonoids (Zhang et al., 2008; Simons et al., 2009). Particularly for 
compound 9, two successive losses of 56 Da were observed from its 
pseudomolecular ion. Based on this observation as well as the suggested molecular 
formula and the RDBeq value, diprenylation could be proposed.  
 
 
Figure 30: HRMS/MS spectrum of compound 3. 
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Figure 31: HRMS/MS spectrum of compound 5. 
 
Figure 32: HRMS/MS spectrum of compound 9. 
 
In contrast, at the HRMS/MS spectra of compounds 4 (Figure 33) (Rt = 12.11 
min), 6 (Figure 34) (Rt = 16.12 min) and 7 (Figure 35) (Rt = 16.69 min),  the 
characteristic loss of 54 Da is observed indicating the presence of a pyran ring 
(Takayama and Nomura, 1995). Moreover, similarly to compound 9, a successive 
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loss of 54 Da was observed at the HRMS/MS spectra of compound 4 indicating 
likewise the presence of two pyran rings on the basic isoflavonoid skeleton.  
 
Figure 33: HRMS/MS spectrum of compound 4. 
 
Figure 34: HRMS/MS spectrum of compound 6. 
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Figure 35: HRMS/MS spectrum of compound 7. 
 
Finally, compound 8 (Figure 36) exhibited both type of mass losses indicating 
probably the concurrent presence of prenyl substitution and pyran ring. 
 
Figure 36: HRMS/MS spectrum of compound 8. 
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4.2 Effects of estrogens and chemicals of plant origin on skeletal 
muscle growth 
4.2.1 E2, genistein, and Ecdysone induce hypertrophy of C2C12 murine skeletal 
muscle cells 
Differentiated C2C12 cells were used as a model to evaluate the effect of 
estrogens, PEs and the phytoecdysteroid ecdysterone on skeletal muscle growth.  As 
shown in Figure 37 all the chemicals except the whole extract and fraction F4 were 
able to significantly increase the diameter of C2C12 myotubes. 
 
Figure 37: Effect of E2, PEs, and the phytoecdysteroid ecdysone on C2C12 myotubes 
hypertrophy. 4-6 days old myotubes incubated for 48 h with test chemicals were fixed and 
photographied by glutaraldehyde induced autofluorescence. Depicted are mean of n≥2 
independent experiments. * p≤0.05 vs.  Control by Kruskal Wallis H-test and Mann Withney 
U-test. 
 
4.2.2 Role of ER and AR on ecdysone induced myotube hypertrophy 
 To get more insights on the mode of action of ecdysterone, further 
experiments were performed with both AR (Flutamide) and ER (ZK) antagonists.  ZK 
but not flutamide was able to block to hypertrophic response of C2C12 myotubes to 
ecdysterone treatment (Figure 38). 
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Figure 38: Role of AR (A) and ER (B) on ecdysterone induced C2C12 myotubes 
hypertrophy. 4-6 days old myotubes incubated for 48 h with test chemicals were fixed and 
photographied by glutaraldehyde induced autofluorescence. Represented are mean± SD of 
n=2 independent experiments. * p≤0.05 vs. Control, + p≤0.05 vs. Single treated Kruskal 
Wallis H-test and Mann Withney U-test. 
 
4.2.3 Role of ERα and ERβ in skeletal muscle growth 
ERs subtype selective agonists (ALPHA and BETA) were used to specify the 
implication of each ER isoform on the hypertrophic response of C2C12 to estrogens 
and estrogen-like chemicals. The dose-response effect of both agonists is 
represented in Figure 39. The increase of mytobute diameter was positively 
correlated with higher concentrations of ALPHA and lower concentrations of BETA. 
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Figure 39: Effect of ER subtype selective agonists on C2C12 myotubes hypertrophy. 4-6 
days old myotubes incubated for 48 h with test chemicals were fixed and photographied by 
glutaraldehyde induced autofluorescence. Depicted are mean of n=3 independent 
experiments. 
 
At a concentration where both agonists selectively bind to their specific 
receptors, BETA but not ALPHA was able to induce myotube hypertrophy (Figure 
40). 
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Figure 40: Effect of ER subtype selective agonists on C2C12 myotubes hypertrophy. 4-6 days old myotubes incubated for 48 h with test 
chemicals were fixed and photographied by glutaraldehyde induced autofluorescence.  Depicted are mean of n=3 independent experiments. * 
p≤0.05 vs. Control by Kruskal Wallis H- and Mann Withney U-tests. 
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Moreover, in the presence of an ERβ selective antagonist the hypertrophic response 
to E2 and Ecdy was reduced (Figure 41) confirming therefore an ERβ-mediated 
effect. 
 
Figure 41: Ecdysterone induced myotube hypertrophy is ERβ-mediated. 4-6 days old 
myotubes incubated for 48 h with test chemicals were fixed and photographied by 
glutaraldehyde induced autofluorescence. * p≤0.05 vs. Control, + p≤0.05 vs. Single treated 
Kruskal Wallis H-test and Mann Withney U-test. 
 
4.2.4 ERα and ERβ expression in C2C12 myotubes 
Both ERs are expressed in differentiated C2C12 cells as shown below (Figure 
42). Expression of ERα was shown at the mRNA level and ERβ at the protein level. 
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Figure 42: ERα mRNA expression (A) and ERβ protein expression (B) in C2C12 myotubes. 
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CHAPTER 5: DISCUSSION 
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The aims of this thesis were to evaluate the biological activities that may 
explain the use of the extract of E. excelsa to alleviate menopausal symptoms and to 
treat female gynecological tumors and to characterize its main chemical constituents; 
and to elucidate the mechanisms underlying the anabolic effect of ecdysterone on 
mammalian skeletal muscle. The major findings that emerged are: 
1. E. excelsa exhibits both estrogenic and antiestrogenic effects on several 
estrogens responsive endpoints. 
 
2.  A phytoestrogenic fraction of E. excelsa at low and maybe 
physiologically relevant concentrations stimulates the growth of MCF-7 
breast cancer cell line in an E2-free environment but exerts antagonistic 
effects in the presence of E2.  
 
3.  Prenyl- and pyran-substituted isoflavonoids are the main constituents 
of E. excelsa extract.  
 
4.  ERβ is involved in Ecdysterone-mediated skeletal muscle growth. 
 
5.1 Biological activities of Erythrina excelsa 
5.1.1 Estrogenic/anti-estrogenic and cytotoxic properties of E. excelsa 
Based on the ethnomedical use of E. excelsa to alleviate menopausal 
complaints and to treat tumors in the female genital tract, we hypothetized that the 
extract may possess estrogenic and cytotoxic properties. The yeast estrogen screen 
(YES) and the uterotrophic assay were used as tests for estrogenicity and the MTT 
assay as test for cytototoxic effects. 
Yeast cells transfected with ERs function as steroid-dependent transcriptional 
activators and are therefore a suitable tool used to measure the ability of a substance 
to activate the transactivation of the receptor. To assess the functionality of our 
assay, the EC50 of E2 was determined and was 86 pM, a value that is comparable to 
the median EC50 value of 100 pM in mammalian cells based transcriptional 
activation assays (The National Toxicology Program (NTP), 2002). Genistein was 
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used as reference phytoestrogen and its calculated EC50, RP and RIE were in line 
with published values (Dhooge et al., 2006). E. excelsa was able to induce a 
concentration-dependent transactivation of ER with a RP of 1.3 x 10-3 which is in the 
range of other RPs reported for estrogenic plants extracts in the YES (Lee et al., 
2005; Zhang et al., 2005). The dose-dependent transactivation of ER by E. excelsa 
was antagonized by a pure anti-estrogen (Figure 14B) demonstrating an ER-
mediated effect. It is worth noting that the calculated potency of the extract was only 
12.3 times lower than that of the pure phytoestrogen genistein suggesting the 
presence of potent estrogenic secondary metabolites in the extract. This was later 
confirmed by LC-HRMS and LC-HRMS/MS analysis which showed that E. excelsa 
whole ethanol extract contains isoflavonoids (Figure 28) known to exhibit estrogenic 
activity in several test systems. 
Because in vitro test systems are usually specific for one mechanism of action 
and cannot totally predict what may happen in an organism, we also used the 3-day 
uterotrophic assay with adult OVX rats according to the OECD guidelines (Owens 
and Ashby, 2002; OECD, 2007) to test the estrogenic activity of E. excelsa. This 
assay is an established model for studying the effect of estrogen and estrogen-like 
substances on estrogen-responsive tissues. Uterine weight is the major endpoint 
measured in the uterotrophic assay as recommended by OECD. However, because 
several PEs and endocrine disruptor substances have been shown to exhibit 
estrogenic effects not visible on the uterine weight, other endpoints (uterine and 
vaginal epithelial heights and uterine and liver gene expression analysis) were also 
included in the investigation.  
Treatment of OVX rats with E.excelsa led to mixed estrogenic and anti-
estrogenic effects on uterine morphometric parameters (Figure 15).The same profile 
was observed at the molecular level on uterine (Figure 16) and liver (Figure 18) gene 
expression. Up-regulation of C3 and down-regulation of clusterin are highly sensitive 
molecular markers to detect estrogenicity in the uterus (Diel et al., 1995). Analysis of 
the uterine expression of these genes in E. excelsa-treated animals indicates a 
strong agonistic activity after treatment with the 50 mg/kg dose, whereas treatment 
with the 100 mg/kg dose resulted in an expression pattern indicative of anti-
estrogenic activity. The liver that is the central organ in metabolic pathways is also a 
non-classical target of estrogen and estrogen-like substances (Geis et al., 2005). The 
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gene expression of IGFBP-1 and CaBP9k in the liver has been shown to be 
upregulated following estradiol administration (Diel et al., 1995; Geis et al., 2005; Lee 
et al., 2005). Here, like in the uterus, E. excelsa exhibited a pattern of activity 
indicative of mixed estrogenic and anti-estrogenic effects. E. excelsa extract contains 
ISO that are known to exhibit hormetic dose-responses on many physiological 
endpoints. Hormesis is defined as the phenomenon by which chemicals are able to 
induce biologically opposite effects at different doses (Siow and Mann, 2010; Vargas 
and Burd, 2010). It is defined in toxicology as a dose-response phenomenon that is 
characterized by low dose stimulation, high dose inhibition, resulting in either a J-
shaped or an inverted U-shaped dose-response. Both estrogenic and anti-estrogenic 
effects of ISO depending on the dose have been reported (Patisaul and Jefferson, 
2010; Pilsakova et al., 2010; Zhao and Mu, 2010). Moreover, according to the MS-
based investigation, pyrano as well as prenylated isoflavonoids comprise the main 
chemical classes of secondary metabolites of the extract. There are several 
published data investigating the role of prenyl chains and pyran rings in the 
estrogenicity of isoflavonoids (Halabalaki et al., 2006; Okamoto, 2006; Djiogue et al., 
2010; Simons et al., 2012). Depending on their position on the isoflavonoids skeleton, 
these substitutions have been shown to modify the biological activity of the parent 
molecule. Djiogue et al (2010) showed that prenylation of genistein at various 
positions was associated with either increase or decrease of its estrogenic 
activity/potency, and with a modification of its ER selectivity. Okamoto et al (2006) 
and Simons et al (2012) on the other hand showed that prenylation at certain 
positions of the isoflavone skeleton was associated with anti-estrogenic activity. 
Okamoto et al (2006) showed that four structural features among which the presence 
of prenyl groups at the 6- and 8-positions of the A-ring of the isoflavone structure are 
essential for the anti-estrogenicity of isoflavones. Tanee Fomum et al. (1986) isolated 
a 5, 7, 4'-trihydroxy-6, 8-diprenylisoflavone from the  stem bark of  E. excelsagrown in 
Cameroon. We therefore suggest that the diprenyl isoflavonoid identified in the 
ethanol extract by LC-MS analysis may correspond to the same compound and may 
also account for the anti-estrogenic effect observed. 
Although the estrogenic response is predominantly mediated by the same ER 
subtype in uterus and vagina, E. excelsa elicited significant estrogenic effects on the 
uterus and not on the vagina. This selectivity of action may be explained by different 
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ratio of coactivators to corepressors proteins or by the fact that the extract may 
induce a different conformation of the ER in both organs. Some authors have 
proposed that phytoestrogens mainly isoflavones due to their mixed agonist 
/antagonistic effects on ER targets may be considered as natural selective estrogen 
receptor modulators (SERMS). For instance, Mersereau et al (2008) showed that 
liquiritigenin, a plant derived phytoestrogen exhibits similar binding affinities for ERα 
and ERβ but induces selective transcriptional change of the ERβ only. To explain this 
difference in transcriptional regulation, they demonstrated that liquiritigenin only 
recruits coactivators to ERβ. Moreover, Shanle and Xu (2011) stated that given the 
importance of coactivators in stimulating transcription and their potential role in 
stabilizing ligand-bound ER in an active conformation, the estrogenic effects of 
potential endocrine disruptors‟ compounds will be highly dependent on the availability 
of coactivators which can vary among cell types, thereby contributing to tissue 
specific effects. 
The effect of E. excelsa on both estrogen-dependent and estrogen-
independent cancer cell lines was investigated using the MTT assay. E. excelsa 
induced a slight increase of the viability of the ER positive MCF-7 cells. This effect 
that may be correlated to an ERα- mediated cell proliferation since we showed in the 
YES that the extract is able to induce the transactivation of ERα. At higher 
concentrations, E. excelsa was cytotoxic on MCF-7 cells, a result that is in agreement 
with the general knowledge on PEs action. It has been shown that this cytotoxic 
effect may be ER-independent as demonstrated here when considering that the 
extract was also cytotoxic on HT-29 cells which are ERα-negative (Hartman et al., 
2009; Edvardsson et al., 2011). There are some evidences suggesting that ERα-
negative cells may have different responses to phytoestrogen exposure. Van der 
Woude et al (2005) demonstrated that the phytoestrogen quercetin at low 
concentrations dose-dependently promoted the growth of the ER-positive MCF-7 
cells and inhibited proliferation at high concentrations. They also showed that 
quercetin in the same concentration range caused a significant inhibition of the 
proliferation of MDA-MB-231 ERα-negative cells. Similarly, genistein was shown to 
increase the growth of estrogen-sensitive cells at low concentrations but decreased 
cell growth at high concentrations (Seo et al., 2006). On HT-29 cells, genistein has 
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been shown to have no effect on the proliferation at low concentration and to inhibit 
cell growth at high concentration (Arai et al., 2000). 
In summary our data demonstrated that E. excelsa exhibits several biological 
activities (estrogenic, antiestrogenic, and cytotoxic) that may explain its 
aforementioned ethnomedical use for women‟s health problems. We also showed 
that prenyl- and pyran-substituted isoflavonoids were the main constituents of the 
extract and may explain the variety of biological activities observed since prenyl 
substitution for example, has been shown to improve interaction with membranes and 
proteins enlarging therefore the range of biological activities. 
5.1.2 Effect of a phytoestrogenic faction of E. excelsa on the growth of the 
human breast cancer line MCF-7. 
Breast cancer is the most common cancer in women with about 60-70% of 
cases classified as ER positive and dependent on estrogens for growth (Mohibi et al., 
2011). Initial results of this work showed that the whole extract of E. excelsa a part 
from its estrogenic effect also inhibit the growth of MCF-7 cells, a wel established in 
vitro model for ER (+) breast cancer. With this backgroung, we then aimed this step 
of our study to get more insights into the “active principle” of the extract accounting 
for these two biological activities. To do this, the ethanol crude extract was 
fractionated over silica gel into five fractions that were further screened for biological 
activity. We concentrated our field of investigations on fractions exhibiting both 
estrogenic and cytotoxic activities. The YES was used as first step screen to select 
estrogenic fractions and the XTT assay used to access their effect on the viability of 
MCF-7 cells. F4 was almost as potent as the whole extract in respect to the 
estrogenic effect but was less cytotoxic suggesting that other non-estrogenic 
compounds of the whole extract may also account for its effects. The HPLC profiling 
method showed that some major compounds present in the whole extract are either 
absent or in low amount in F4 (Figure 22). 
To gain more understanding of the mechanisms underlying F4-effect on the 
growth of MCF-7 cells, cell cycle analysis was performed following 48h-treatment with 
increasing concentrations (1-100 µg/ml). At Lower concentrations, F4 similar to E2 
promoted cell cycle progression and inhibited cell death (Figure 23) and this effect 
was ER-dependent (Figure 24). Gene expression analysis showed that F4 at low 
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concentration like E2 increased CCND1 level and modulated the Bax/Bcl-2 ratio in 
favor of cell survival (Figure 27). Cell cycle progression is a tightly controlled process 
controlled by cyclins and cyclin-dependent kinases (CDKs) complexes and the 
deregulation of their expression frequently impacts on breast cancer outcome 
including response to therapy (Nigg, 1995; Caldon et al., 2006). CyclinD1 along with 
its binding CDKs is an essential sensor and activator of cell cycle initiation and 
progression (particularly the transition from G1 to S-phase) and is overexpressed in 
up to 50% of human invasive breast cancers (Sun et al., 2012). Bcl-2 family members 
play an important role in the mediation and regulation of apoptotic signaling pathways 
acting to either inhibit (e.g. Bcl-2) or promote cell death (e.g. Bax). The Bax/Bcl-2 
ratio has been recognized as a key factor and determines whether a cell will undergo 
apoptosis (Leung and Wang, 1999; Gewies, 2003). As CCND1, Bcl-2 overexpression 
is common in breast cancer (Oakes et al., 2011). It is well known that estrogens 
through several mechanisms among which their stimulating effects on cell cycle 
progression and pro-survival Bcl-2 are an important risk factor for breast cancer 
development and progression  (Sutherland et al., 1995).  F4 at low and maybe 
physiologically relevant concentrations behaved in the same way. However, the 
relevance of this result for the in vivo situation where the mammary gland is 
surrounded by other tissues and is under the influence of growth factors and other 
hormones is still to be determined.  In fact the local estrogen level in the tissue, the 
expressed cofactors, and the expression level of ERα and ERβ are important factors 
to take into consideration when considering the in vivo situation (Bondesson and 
Gustafsson, 2010). For instance PEs have been shown to exhibit antagonistic 
properties in the presence of E2 and this ability was also confirmed here as we 
showed that F4 at the same concentration range where growth stimulation was 
observed, acted as an antagonist in the presence of E2. This antagonistic ability may 
be of interest because it is generally believed that treatments that trigger ER 
antagonist effects are protective against breast cancer and favorably affect the 
course of breast cancer once diagnosed (Bolca et al., 2010). 
At higher concentrations, F4 modulated the G1/S transition as confirmed by 
decreased CCND1 mRNA level and induced apoptosis sustained by M30 staining 
results and increased Bax/ Bcl-2 ratio (Figures 23, 26, and 27). Impairment of 
apoptosis is implicated in not only cancer development but also in the therapy 
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(Adams and Cory, 2007). Cancer cells are resistant to apoptosis and it is proposed 
that drugs or treatment strategies that can restore the apoptotic signaling pathways 
towards normality have the potential to eliminate cancer cells (Wong, 2011). It is 
however worth to note that this effect was achieved with relatively high and probably 
supraphysiologic concentrations of the extract fraction.  
Cotreatment with E2 and higher concentrations of F4 induced more cells to 
transit from G1 to S as compared to single F4 treatment. But at the same time an 
increase of the percentage of cells in SubG1 was observed. At high concentrations 
F4 acted almost the same way as the pure antiestrogen ZK with the difference that 
ZK caused cell cycle arrest whereas F4 blocked G1/S transition without preventing 
the cells to transit from S to G2/M. (Dalvai and Bystricky, 2010) showed that cells in 
the S-phase are more sensitive to antiestrogens-induced apoptosis. Therefore, 
cotreatment with E2 by inducing more cells transit from G1 to S also increases their 
susceptibility to undergo F4 induced cell death.  
 Overall these results show that F4 has a biphasic profile on the growth MCF-7 
breast cancer cells: low dose stimulation and high dose inhibition through induction of 
apoptosis. However, whether this is relevant for breast cancer outcomes is still to be 
determined because a direct translation of in vitro results to the in vivo situation would 
be oversimplifying and unrealistic. One interesting aspect is that the effects of low 
and physiologically relevant concentrations of F4 depended on the presence or 
absence of E2. In the presence of E2, F4 could counteract E2-induced stimulation of 
cancer cells growth and may therefore be of significance and of interest for 
premenopausal women.  
 
5.2 Effect of estrogens and chemicals of plant origin on C2C12 
murine skeletal muscle cells growth. 
Increasing evidences have emerged over the past decades indicating that 
estrogens can regulate skeletal muscle mass (established by a net difference 
between muscle protein synthesis rate and muscle protein breakdown). Galluzzo et al 
(2009) proposed that estrogens (E2) should be included in the list of skeletal muscle 
trophic factors. Skeletal muscle hypertrophy is a dynamic process involving both an 
increase in the number of nuclei (due to the stimulation of the proliferation, 
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differentiation and fusion of quiescent satellite cells) as well as an increase in 
cytoplasmic volume (due to an increase in protein synthesis or remodeling). Here, we 
were interested in the effects of our test chemicals on the increase in cytoplamic 
volume. Therefore, to differentiate between effects on myoblast differentiation and 
those on the trophic state of existing myofibers, fusion of C2C12 myoblasts towards 
myotubes was induced prior to the treatment. E2, genistein and Ecdy induced a 
significant increase of myotube diameter compared to untreated myotubes probably 
due to a shift of the balance in favor of protein synthesis. The Akt signaling pathway 
plays an important role in skeletal muscle hypertrophy. E2 (Stefanetti et al, 2008), 
and Ecdy (Gorelick-Feldman et al, 2010) have been shown to increase Akt activity 
and its downstream anabolic signaling proteins. Conversely to Ecdy that increase the 
protein synthesis in the muscle, E2 and genistein have been shown to rather 
decrease protein breakdown in porcine skeletal muscle cells (Mau, 2007). 
As previously shown by others (Kahlert et al., 1997; Galluzzo et al., 2009; 
Milanesi et al., 2009), the presence of both ER isoforms in C2C12 cells was 
confirmed in this study. We also showed for the first time that the Ecdy-induced 
hypertrophic response is ER-mediated (Figure 38). ERα and ERβ selective agonists 
were used to further elucidate the contribution of each ER subtype on E2 and Ecdy-
induced myotube hypertrophy. 16α-LE2 (ALPHA) and 8β-VE2 (BETA) are subtype-
selective steroidal ER agonists designed on the basis of the available protein 
structure information (Hillisch et al., 2004). In a transactivation assay with APHA and 
BETA, Hillisch et al (2004) showed that the selectivity of both agonists was lost when 
used at higher concentrations (Figure 43). Based on this knowledge, dose-response 
effects of each agonist were investigated and the results demonstrated that the 
hypertrophic response was ERβ-mediated. Moreover, the use of an ERβ antagonist 
allowed us to unequivocally show that E2 and Ecdy-induced hypertrophy is mediated 
through ERβ (Figure 41). With respect to E2, these results are in line with previous 
findings of our lab which indicate that the anabolic effect of E2 is primordially ERβ-
mediated (Velders et al., 2012; Weigt et al., 2012) but are in contradiction with the 
findings of Galluzzo et al (2009) who found that ERα was the principal mediator of E2 
effect in skeletal muscle. However, it is worth to note that their experiments were 
performed on differentiating myotubes, while we used already differentiated 
myotubes. With respect to Ecdy, published data on its ability to bind ERs are 
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conflicting. Gao et al (2008) showed that Ecdy was able to transactivate ERβ in 
embryonic kidney stem cells (293T) transfected with ERβ expression vector. Others 
(Bathori et al., 2008; Seidlova-Wuttke et al., 2010) however demonstrated that Ecdy 
was not able to bind ER.  
 
 
Figure 43: Transactivation studies with ERα agonist (16α-LE2) and ERβ agonist (8β-VE2) in 
comparison to E2 (Hillisch et al., 2004) 
 
In summary, we successfully used a system with differentiated C2C12 
myoblasts to demonstrate the skeletal muscle growth promoting effects of E2, the 
phytoestrogen genistein, and the phytoecdysteroid ecdysterone. Moreover, we 
confirmed the results of previous studies showing that ERβ was the ER isoform 
mediating E2 anabolic effects, and showed for the first time that the anabolic effect of 
Ecdy is ERβ-mediated. 
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The aim of the present thesis was to investigate the biological activities and 
mechanisms of action of two plant-related chemicals either as an extract or as a pure 
compound. The results showed that an ethanol extract of Erythrina excelsa Baker 
exhibits estrogenic and cytotoxic effects that are in close agreement with its 
traditionally reported use to alleviate menopausal complaints and to treat female 
gynaecological tumors. Chemical characterization revealed a rich metabolic content 
of the extract and the isolation of the characterized compounds is ongoing with the 
aim to investigate their biological activities as single compounds. We also confirmed 
the anabolic efficiency of Ecdysterone and showed for the first time that it is ERβ-
mediated, a result that is of interest and may provide new insights not only for 
strategies aiming to treat health conditions related to muscle atrophy (sarcopenia, 
Duchenne myopathy), but also for doping. Overall, the findings of this thesis show 
that although traditional medicine is often regarded with a lot of skepticism, it may 
provide helpful basic knowledge for research orientation. In an era marked by 
worldwide increase in life expectancy and its associated chronic diseases, the 
maintenance of good health and quality of life is a challenging global issue involving 
both developed and developing countries. The potential of traditional medicine is 
increasingly recognized but a lot of effort is still needed in other to attain an evidence-
based utilization.  
With respect to breast cancer risk, one interesting result that emerged from our 
investigations confirming previous recommendations is that local estrogens levels is 
an important factor to take into consideration when considering phytoestrogens 
consumption and breast cancer outcomes. Intensive research has been made over 
the last decade to clarify whether phytoestrogens could be an alternative to hormone 
replacement therapy (HRT). Unfortunately most of the performed human clinical trials 
failed to show clear evidences. To my opinion, strategies combining HRT and 
phytoestrogens maybe of more interest in the future. 
 
Limitations and recommendations for further research 
 
The results of this thesis give an overview of the possible biological activity of 
E.excelsa but do not provide sufficient understanding to enable specific 
recommandations for use. With respect to Ecdysterone, although we clearly show 
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that its skeletal muscle growth promoting effects are ERβ- mediated, published data 
regarding its ER binding ability are conflicting. Future investigations should clarify this 
issue. 
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